Scope, units and essential conditions
For infants born ≥35 weeks. GA is already built into each grid; do not automatically select an additional-risk grid for GA alone. Use total serum bilirubin without subtracting direct/conjugated bilirubin. If that fraction exceeds 50% in severe hyperbilirubinemia, seek expert input. Thresholds rest on expert opinion; they are not a proven boundary of benefit versus harm.
Exchange curves have particular uncertainty in the first 24 h. Acute bilirubin encephalopathy is an independent urgent-exchange indication. Escalation begins at 2 mg/dL below the appropriate exchange threshold. This is not a replacement for the locally readable monitoring, hemolysis, escalation and follow-up recommendations.
These are AAP grids, not CPS or NICE thresholds. Where a source footnote gives a plateau age, that note is shown; shorter printed grids are not extrapolated by the app. The source prints 14 full completed days for several grids; values are transcribed as printed, without adding later ages.
AAP 2022 guideline and Supplemental Tables 1–4 · Published August 5, 2022 (September issue) · Checked October 27, 2026.
Phototherapy · no additional neurotoxicity risks
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥96 h (eg, 4 completed days) after birth is 21.8 mg/dL.
Completed day 0
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 8.9 |
|---|
| 2 | 9.1 |
|---|
| 3 | 9.3 |
|---|
| 4 | 9.6 |
|---|
| 5 | 9.8 |
|---|
| 6 | 10.0 |
|---|
| 7 | 10.2 |
|---|
| 8 | 10.4 |
|---|
| 9 | 10.5 |
|---|
| 10 | 10.7 |
|---|
| 11 | 10.9 |
|---|
| 12 | 11.1 |
|---|
| 13 | 11.3 |
|---|
| 14 | 11.5 |
|---|
| 15 | 11.7 |
|---|
| 16 | 11.9 |
|---|
| 17 | 12.1 |
|---|
| 18 | 12.2 |
|---|
| 19 | 12.4 |
|---|
| 20 | 12.6 |
|---|
| 21 | 12.8 |
|---|
| 22 | 13.0 |
|---|
| 23 | 13.1 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 13.3 |
|---|
| 1 | 13.5 |
|---|
| 2 | 13.6 |
|---|
| 3 | 13.8 |
|---|
| 4 | 14.0 |
|---|
| 5 | 14.1 |
|---|
| 6 | 14.3 |
|---|
| 7 | 14.5 |
|---|
| 8 | 14.6 |
|---|
| 9 | 14.8 |
|---|
| 10 | 15.0 |
|---|
| 11 | 15.1 |
|---|
| 12 | 15.3 |
|---|
| 13 | 15.4 |
|---|
| 14 | 15.6 |
|---|
| 15 | 15.7 |
|---|
| 16 | 15.9 |
|---|
| 17 | 16.0 |
|---|
| 18 | 16.2 |
|---|
| 19 | 16.3 |
|---|
| 20 | 16.4 |
|---|
| 21 | 16.6 |
|---|
| 22 | 16.7 |
|---|
| 23 | 16.9 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.0 |
|---|
| 1 | 17.1 |
|---|
| 2 | 17.3 |
|---|
| 3 | 17.4 |
|---|
| 4 | 17.5 |
|---|
| 5 | 17.7 |
|---|
| 6 | 17.8 |
|---|
| 7 | 17.9 |
|---|
| 8 | 18.0 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.3 |
|---|
| 11 | 18.4 |
|---|
| 12 | 18.5 |
|---|
| 13 | 18.6 |
|---|
| 14 | 18.8 |
|---|
| 15 | 18.9 |
|---|
| 16 | 19.0 |
|---|
| 17 | 19.1 |
|---|
| 18 | 19.2 |
|---|
| 19 | 19.3 |
|---|
| 20 | 19.4 |
|---|
| 21 | 19.6 |
|---|
| 22 | 19.7 |
|---|
| 23 | 19.7 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.8 |
|---|
| 1 | 19.9 |
|---|
| 2 | 20.0 |
|---|
| 3 | 20.1 |
|---|
| 4 | 20.2 |
|---|
| 5 | 20.3 |
|---|
| 6 | 20.4 |
|---|
| 7 | 20.5 |
|---|
| 8 | 20.6 |
|---|
| 9 | 20.7 |
|---|
| 10 | 20.7 |
|---|
| 11 | 20.8 |
|---|
| 12 | 20.9 |
|---|
| 13 | 21.0 |
|---|
| 14 | 21.1 |
|---|
| 15 | 21.1 |
|---|
| 16 | 21.2 |
|---|
| 17 | 21.3 |
|---|
| 18 | 21.4 |
|---|
| 19 | 21.4 |
|---|
| 20 | 21.5 |
|---|
| 21 | 21.6 |
|---|
| 22 | 21.6 |
|---|
| 23 | 21.7 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 40+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.8 |
|---|
| 1 | 21.8 |
|---|
| 2 | 21.8 |
|---|
| 3 | 21.8 |
|---|
| 4 | 21.8 |
|---|
| 5 | 21.8 |
|---|
| 6 | 21.8 |
|---|
| 7 | 21.8 |
|---|
| 8 | 21.8 |
|---|
| 9 | 21.8 |
|---|
| 10 | 21.8 |
|---|
| 11 | 21.8 |
|---|
| 12 | 21.8 |
|---|
| 13 | 21.8 |
|---|
| 14 | 21.8 |
|---|
| 15 | 21.8 |
|---|
| 16 | 21.8 |
|---|
| 17 | 21.8 |
|---|
| 18 | 21.8 |
|---|
| 19 | 21.8 |
|---|
| 20 | 21.8 |
|---|
| 21 | 21.8 |
|---|
| 22 | 21.8 |
|---|
| 23 | 21.8 |
|---|
AAP 2022 · Supplemental Table 1, PDF p20 →
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥157 h (eg, 6 completed days and 13 h) after birth is 21.8 mg/dL.
Completed day 0
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 8.4 |
|---|
| 2 | 8.6 |
|---|
| 3 | 8.8 |
|---|
| 4 | 9.0 |
|---|
| 5 | 9.3 |
|---|
| 6 | 9.5 |
|---|
| 7 | 9.7 |
|---|
| 8 | 9.9 |
|---|
| 9 | 10.0 |
|---|
| 10 | 10.2 |
|---|
| 11 | 10.4 |
|---|
| 12 | 10.6 |
|---|
| 13 | 10.8 |
|---|
| 14 | 11.0 |
|---|
| 15 | 11.2 |
|---|
| 16 | 11.4 |
|---|
| 17 | 11.6 |
|---|
| 18 | 11.8 |
|---|
| 19 | 11.9 |
|---|
| 20 | 12.1 |
|---|
| 21 | 12.3 |
|---|
| 22 | 12.5 |
|---|
| 23 | 12.7 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 12.8 |
|---|
| 1 | 13.0 |
|---|
| 2 | 13.2 |
|---|
| 3 | 13.3 |
|---|
| 4 | 13.5 |
|---|
| 5 | 13.7 |
|---|
| 6 | 13.8 |
|---|
| 7 | 14.0 |
|---|
| 8 | 14.2 |
|---|
| 9 | 14.3 |
|---|
| 10 | 14.5 |
|---|
| 11 | 14.7 |
|---|
| 12 | 14.8 |
|---|
| 13 | 15.0 |
|---|
| 14 | 15.1 |
|---|
| 15 | 15.3 |
|---|
| 16 | 15.4 |
|---|
| 17 | 15.6 |
|---|
| 18 | 15.7 |
|---|
| 19 | 15.9 |
|---|
| 20 | 16.0 |
|---|
| 21 | 16.2 |
|---|
| 22 | 16.3 |
|---|
| 23 | 16.4 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.6 |
|---|
| 1 | 16.7 |
|---|
| 2 | 16.8 |
|---|
| 3 | 17.0 |
|---|
| 4 | 17.1 |
|---|
| 5 | 17.2 |
|---|
| 6 | 17.4 |
|---|
| 7 | 17.5 |
|---|
| 8 | 17.6 |
|---|
| 9 | 17.8 |
|---|
| 10 | 17.9 |
|---|
| 11 | 18.0 |
|---|
| 12 | 18.1 |
|---|
| 13 | 18.2 |
|---|
| 14 | 18.4 |
|---|
| 15 | 18.5 |
|---|
| 16 | 18.6 |
|---|
| 17 | 18.7 |
|---|
| 18 | 18.8 |
|---|
| 19 | 18.9 |
|---|
| 20 | 19.0 |
|---|
| 21 | 19.1 |
|---|
| 22 | 19.2 |
|---|
| 23 | 19.3 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.5 |
|---|
| 1 | 19.6 |
|---|
| 2 | 19.7 |
|---|
| 3 | 19.7 |
|---|
| 4 | 19.8 |
|---|
| 5 | 19.9 |
|---|
| 6 | 20.0 |
|---|
| 7 | 20.1 |
|---|
| 8 | 20.2 |
|---|
| 9 | 20.3 |
|---|
| 10 | 20.4 |
|---|
| 11 | 20.5 |
|---|
| 12 | 20.6 |
|---|
| 13 | 20.6 |
|---|
| 14 | 20.7 |
|---|
| 15 | 20.8 |
|---|
| 16 | 20.9 |
|---|
| 17 | 21.0 |
|---|
| 18 | 21.0 |
|---|
| 19 | 21.1 |
|---|
| 20 | 21.2 |
|---|
| 21 | 21.3 |
|---|
| 22 | 21.3 |
|---|
| 23 | 21.4 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.5 |
|---|
| 1 | 21.5 |
|---|
| 2 | 21.5 |
|---|
| 3 | 21.5 |
|---|
| 4 | 21.5 |
|---|
| 5 | 21.5 |
|---|
| 6 | 21.5 |
|---|
| 7 | 21.5 |
|---|
| 8 | 21.5 |
|---|
| 9 | 21.5 |
|---|
| 10 | 21.5 |
|---|
| 11 | 21.5 |
|---|
| 12 | 21.5 |
|---|
| 13 | 21.5 |
|---|
| 14 | 21.6 |
|---|
| 15 | 21.6 |
|---|
| 16 | 21.6 |
|---|
| 17 | 21.6 |
|---|
| 18 | 21.6 |
|---|
| 19 | 21.6 |
|---|
| 20 | 21.6 |
|---|
| 21 | 21.6 |
|---|
| 22 | 21.6 |
|---|
| 23 | 21.6 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.6 |
|---|
| 1 | 21.6 |
|---|
| 2 | 21.6 |
|---|
| 3 | 21.6 |
|---|
| 4 | 21.6 |
|---|
| 5 | 21.6 |
|---|
| 6 | 21.6 |
|---|
| 7 | 21.6 |
|---|
| 8 | 21.6 |
|---|
| 9 | 21.6 |
|---|
| 10 | 21.6 |
|---|
| 11 | 21.6 |
|---|
| 12 | 21.6 |
|---|
| 13 | 21.6 |
|---|
| 14 | 21.7 |
|---|
| 15 | 21.7 |
|---|
| 16 | 21.7 |
|---|
| 17 | 21.7 |
|---|
| 18 | 21.7 |
|---|
| 19 | 21.7 |
|---|
| 20 | 21.7 |
|---|
| 21 | 21.7 |
|---|
| 22 | 21.7 |
|---|
| 23 | 21.7 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 39 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.7 |
|---|
| 1 | 21.7 |
|---|
| 2 | 21.7 |
|---|
| 3 | 21.7 |
|---|
| 4 | 21.7 |
|---|
| 5 | 21.7 |
|---|
| 6 | 21.7 |
|---|
| 7 | 21.7 |
|---|
| 8 | 21.7 |
|---|
| 9 | 21.7 |
|---|
| 10 | 21.7 |
|---|
| 11 | 21.7 |
|---|
| 12 | 21.7 |
|---|
| 13 | 21.8 |
|---|
| 14 | 21.8 |
|---|
| 15 | 21.8 |
|---|
| 16 | 21.8 |
|---|
| 17 | 21.8 |
|---|
| 18 | 21.8 |
|---|
| 19 | 21.8 |
|---|
| 20 | 21.8 |
|---|
| 21 | 21.8 |
|---|
| 22 | 21.8 |
|---|
| 23 | 21.8 |
|---|
AAP 2022 · Supplemental Table 1, PDF p20 →
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥325 h (eg, 13 completed days and 13 h) after birth is 21.8 mg/dL.
Completed day 0
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 7.9 |
|---|
| 2 | 8.1 |
|---|
| 3 | 8.3 |
|---|
| 4 | 8.5 |
|---|
| 5 | 8.7 |
|---|
| 6 | 8.9 |
|---|
| 7 | 9.1 |
|---|
| 8 | 9.3 |
|---|
| 9 | 9.5 |
|---|
| 10 | 9.7 |
|---|
| 11 | 9.9 |
|---|
| 12 | 10.1 |
|---|
| 13 | 10.3 |
|---|
| 14 | 10.5 |
|---|
| 15 | 10.7 |
|---|
| 16 | 10.8 |
|---|
| 17 | 11.0 |
|---|
| 18 | 11.2 |
|---|
| 19 | 11.4 |
|---|
| 20 | 11.6 |
|---|
| 21 | 11.7 |
|---|
| 22 | 11.9 |
|---|
| 23 | 12.1 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 12.3 |
|---|
| 1 | 12.4 |
|---|
| 2 | 12.6 |
|---|
| 3 | 12.8 |
|---|
| 4 | 12.9 |
|---|
| 5 | 13.1 |
|---|
| 6 | 13.3 |
|---|
| 7 | 13.4 |
|---|
| 8 | 13.6 |
|---|
| 9 | 13.8 |
|---|
| 10 | 13.9 |
|---|
| 11 | 14.1 |
|---|
| 12 | 14.2 |
|---|
| 13 | 14.4 |
|---|
| 14 | 14.5 |
|---|
| 15 | 14.7 |
|---|
| 16 | 14.8 |
|---|
| 17 | 15.0 |
|---|
| 18 | 15.1 |
|---|
| 19 | 15.3 |
|---|
| 20 | 15.4 |
|---|
| 21 | 15.6 |
|---|
| 22 | 15.7 |
|---|
| 23 | 15.8 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.0 |
|---|
| 1 | 16.1 |
|---|
| 2 | 16.2 |
|---|
| 3 | 16.4 |
|---|
| 4 | 16.5 |
|---|
| 5 | 16.6 |
|---|
| 6 | 16.8 |
|---|
| 7 | 16.9 |
|---|
| 8 | 17.0 |
|---|
| 9 | 17.1 |
|---|
| 10 | 17.3 |
|---|
| 11 | 17.4 |
|---|
| 12 | 17.5 |
|---|
| 13 | 17.6 |
|---|
| 14 | 17.7 |
|---|
| 15 | 17.8 |
|---|
| 16 | 17.9 |
|---|
| 17 | 18.1 |
|---|
| 18 | 18.2 |
|---|
| 19 | 18.3 |
|---|
| 20 | 18.4 |
|---|
| 21 | 18.5 |
|---|
| 22 | 18.6 |
|---|
| 23 | 18.7 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.8 |
|---|
| 1 | 18.9 |
|---|
| 2 | 19.0 |
|---|
| 3 | 19.1 |
|---|
| 4 | 19.2 |
|---|
| 5 | 19.3 |
|---|
| 6 | 19.4 |
|---|
| 7 | 19.5 |
|---|
| 8 | 19.5 |
|---|
| 9 | 19.6 |
|---|
| 10 | 19.7 |
|---|
| 11 | 19.8 |
|---|
| 12 | 19.9 |
|---|
| 13 | 20.0 |
|---|
| 14 | 20.0 |
|---|
| 15 | 20.1 |
|---|
| 16 | 20.2 |
|---|
| 17 | 20.3 |
|---|
| 18 | 20.3 |
|---|
| 19 | 20.4 |
|---|
| 20 | 20.5 |
|---|
| 21 | 20.6 |
|---|
| 22 | 20.6 |
|---|
| 23 | 20.7 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.7 |
|---|
| 1 | 20.8 |
|---|
| 2 | 20.8 |
|---|
| 3 | 20.8 |
|---|
| 4 | 20.8 |
|---|
| 5 | 20.8 |
|---|
| 6 | 20.8 |
|---|
| 7 | 20.8 |
|---|
| 8 | 20.8 |
|---|
| 9 | 20.8 |
|---|
| 10 | 20.8 |
|---|
| 11 | 20.8 |
|---|
| 12 | 20.8 |
|---|
| 13 | 20.8 |
|---|
| 14 | 20.8 |
|---|
| 15 | 20.8 |
|---|
| 16 | 20.8 |
|---|
| 17 | 20.8 |
|---|
| 18 | 20.8 |
|---|
| 19 | 20.9 |
|---|
| 20 | 20.9 |
|---|
| 21 | 20.9 |
|---|
| 22 | 20.9 |
|---|
| 23 | 20.9 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.9 |
|---|
| 1 | 20.9 |
|---|
| 2 | 20.9 |
|---|
| 3 | 20.9 |
|---|
| 4 | 20.9 |
|---|
| 5 | 20.9 |
|---|
| 6 | 20.9 |
|---|
| 7 | 20.9 |
|---|
| 8 | 20.9 |
|---|
| 9 | 20.9 |
|---|
| 10 | 20.9 |
|---|
| 11 | 20.9 |
|---|
| 12 | 20.9 |
|---|
| 13 | 20.9 |
|---|
| 14 | 20.9 |
|---|
| 15 | 20.9 |
|---|
| 16 | 20.9 |
|---|
| 17 | 20.9 |
|---|
| 18 | 21.0 |
|---|
| 19 | 21.0 |
|---|
| 20 | 21.0 |
|---|
| 21 | 21.0 |
|---|
| 22 | 21.0 |
|---|
| 23 | 21.0 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.0 |
|---|
| 1 | 21.0 |
|---|
| 2 | 21.0 |
|---|
| 3 | 21.0 |
|---|
| 4 | 21.0 |
|---|
| 5 | 21.0 |
|---|
| 6 | 21.0 |
|---|
| 7 | 21.0 |
|---|
| 8 | 21.0 |
|---|
| 9 | 21.0 |
|---|
| 10 | 21.0 |
|---|
| 11 | 21.0 |
|---|
| 12 | 21.0 |
|---|
| 13 | 21.0 |
|---|
| 14 | 21.0 |
|---|
| 15 | 21.0 |
|---|
| 16 | 21.0 |
|---|
| 17 | 21.0 |
|---|
| 18 | 21.1 |
|---|
| 19 | 21.1 |
|---|
| 20 | 21.1 |
|---|
| 21 | 21.1 |
|---|
| 22 | 21.1 |
|---|
| 23 | 21.1 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.1 |
|---|
| 1 | 21.1 |
|---|
| 2 | 21.1 |
|---|
| 3 | 21.1 |
|---|
| 4 | 21.1 |
|---|
| 5 | 21.1 |
|---|
| 6 | 21.1 |
|---|
| 7 | 21.1 |
|---|
| 8 | 21.1 |
|---|
| 9 | 21.1 |
|---|
| 10 | 21.1 |
|---|
| 11 | 21.1 |
|---|
| 12 | 21.1 |
|---|
| 13 | 21.1 |
|---|
| 14 | 21.1 |
|---|
| 15 | 21.1 |
|---|
| 16 | 21.1 |
|---|
| 17 | 21.2 |
|---|
| 18 | 21.2 |
|---|
| 19 | 21.2 |
|---|
| 20 | 21.2 |
|---|
| 21 | 21.2 |
|---|
| 22 | 21.2 |
|---|
| 23 | 21.2 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.2 |
|---|
| 1 | 21.2 |
|---|
| 2 | 21.2 |
|---|
| 3 | 21.2 |
|---|
| 4 | 21.2 |
|---|
| 5 | 21.2 |
|---|
| 6 | 21.2 |
|---|
| 7 | 21.2 |
|---|
| 8 | 21.2 |
|---|
| 9 | 21.2 |
|---|
| 10 | 21.2 |
|---|
| 11 | 21.2 |
|---|
| 12 | 21.2 |
|---|
| 13 | 21.2 |
|---|
| 14 | 21.2 |
|---|
| 15 | 21.2 |
|---|
| 16 | 21.3 |
|---|
| 17 | 21.3 |
|---|
| 18 | 21.3 |
|---|
| 19 | 21.3 |
|---|
| 20 | 21.3 |
|---|
| 21 | 21.3 |
|---|
| 22 | 21.3 |
|---|
| 23 | 21.3 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.3 |
|---|
| 1 | 21.3 |
|---|
| 2 | 21.3 |
|---|
| 3 | 21.3 |
|---|
| 4 | 21.3 |
|---|
| 5 | 21.3 |
|---|
| 6 | 21.3 |
|---|
| 7 | 21.3 |
|---|
| 8 | 21.3 |
|---|
| 9 | 21.3 |
|---|
| 10 | 21.3 |
|---|
| 11 | 21.3 |
|---|
| 12 | 21.3 |
|---|
| 13 | 21.3 |
|---|
| 14 | 21.3 |
|---|
| 15 | 21.4 |
|---|
| 16 | 21.4 |
|---|
| 17 | 21.4 |
|---|
| 18 | 21.4 |
|---|
| 19 | 21.4 |
|---|
| 20 | 21.4 |
|---|
| 21 | 21.4 |
|---|
| 22 | 21.4 |
|---|
| 23 | 21.4 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.4 |
|---|
| 1 | 21.4 |
|---|
| 2 | 21.4 |
|---|
| 3 | 21.4 |
|---|
| 4 | 21.4 |
|---|
| 5 | 21.4 |
|---|
| 6 | 21.4 |
|---|
| 7 | 21.4 |
|---|
| 8 | 21.4 |
|---|
| 9 | 21.4 |
|---|
| 10 | 21.4 |
|---|
| 11 | 21.4 |
|---|
| 12 | 21.4 |
|---|
| 13 | 21.4 |
|---|
| 14 | 21.4 |
|---|
| 15 | 21.5 |
|---|
| 16 | 21.5 |
|---|
| 17 | 21.5 |
|---|
| 18 | 21.5 |
|---|
| 19 | 21.5 |
|---|
| 20 | 21.5 |
|---|
| 21 | 21.5 |
|---|
| 22 | 21.5 |
|---|
| 23 | 21.5 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.5 |
|---|
| 1 | 21.5 |
|---|
| 2 | 21.5 |
|---|
| 3 | 21.5 |
|---|
| 4 | 21.5 |
|---|
| 5 | 21.5 |
|---|
| 6 | 21.5 |
|---|
| 7 | 21.5 |
|---|
| 8 | 21.5 |
|---|
| 9 | 21.5 |
|---|
| 10 | 21.5 |
|---|
| 11 | 21.5 |
|---|
| 12 | 21.5 |
|---|
| 13 | 21.5 |
|---|
| 14 | 21.6 |
|---|
| 15 | 21.6 |
|---|
| 16 | 21.6 |
|---|
| 17 | 21.6 |
|---|
| 18 | 21.6 |
|---|
| 19 | 21.6 |
|---|
| 20 | 21.6 |
|---|
| 21 | 21.6 |
|---|
| 22 | 21.6 |
|---|
| 23 | 21.6 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.6 |
|---|
| 1 | 21.6 |
|---|
| 2 | 21.6 |
|---|
| 3 | 21.6 |
|---|
| 4 | 21.6 |
|---|
| 5 | 21.6 |
|---|
| 6 | 21.6 |
|---|
| 7 | 21.6 |
|---|
| 8 | 21.6 |
|---|
| 9 | 21.6 |
|---|
| 10 | 21.6 |
|---|
| 11 | 21.6 |
|---|
| 12 | 21.6 |
|---|
| 13 | 21.6 |
|---|
| 14 | 21.7 |
|---|
| 15 | 21.7 |
|---|
| 16 | 21.7 |
|---|
| 17 | 21.7 |
|---|
| 18 | 21.7 |
|---|
| 19 | 21.7 |
|---|
| 20 | 21.7 |
|---|
| 21 | 21.7 |
|---|
| 22 | 21.7 |
|---|
| 23 | 21.7 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 38 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.7 |
|---|
| 1 | 21.7 |
|---|
| 2 | 21.7 |
|---|
| 3 | 21.7 |
|---|
| 4 | 21.7 |
|---|
| 5 | 21.7 |
|---|
| 6 | 21.7 |
|---|
| 7 | 21.7 |
|---|
| 8 | 21.7 |
|---|
| 9 | 21.7 |
|---|
| 10 | 21.7 |
|---|
| 11 | 21.7 |
|---|
| 12 | 21.7 |
|---|
| 13 | 21.8 |
|---|
| 14 | 21.8 |
|---|
| 15 | 21.8 |
|---|
| 16 | 21.8 |
|---|
| 17 | 21.8 |
|---|
| 18 | 21.8 |
|---|
| 19 | 21.8 |
|---|
| 20 | 21.8 |
|---|
| 21 | 21.8 |
|---|
| 22 | 21.8 |
|---|
| 23 | 21.8 |
|---|
AAP 2022 · Supplemental Table 1, PDF p20 →
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 7.4 |
|---|
| 2 | 7.6 |
|---|
| 3 | 7.8 |
|---|
| 4 | 8.0 |
|---|
| 5 | 8.2 |
|---|
| 6 | 8.4 |
|---|
| 7 | 8.6 |
|---|
| 8 | 8.8 |
|---|
| 9 | 9.0 |
|---|
| 10 | 9.2 |
|---|
| 11 | 9.4 |
|---|
| 12 | 9.6 |
|---|
| 13 | 9.8 |
|---|
| 14 | 9.9 |
|---|
| 15 | 10.1 |
|---|
| 16 | 10.3 |
|---|
| 17 | 10.5 |
|---|
| 18 | 10.7 |
|---|
| 19 | 10.8 |
|---|
| 20 | 11.0 |
|---|
| 21 | 11.2 |
|---|
| 22 | 11.4 |
|---|
| 23 | 11.5 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 11.7 |
|---|
| 1 | 11.9 |
|---|
| 2 | 12.1 |
|---|
| 3 | 12.2 |
|---|
| 4 | 12.4 |
|---|
| 5 | 12.5 |
|---|
| 6 | 12.7 |
|---|
| 7 | 12.9 |
|---|
| 8 | 13.0 |
|---|
| 9 | 13.2 |
|---|
| 10 | 13.3 |
|---|
| 11 | 13.5 |
|---|
| 12 | 13.6 |
|---|
| 13 | 13.8 |
|---|
| 14 | 13.9 |
|---|
| 15 | 14.1 |
|---|
| 16 | 14.2 |
|---|
| 17 | 14.4 |
|---|
| 18 | 14.5 |
|---|
| 19 | 14.7 |
|---|
| 20 | 14.8 |
|---|
| 21 | 15.0 |
|---|
| 22 | 15.1 |
|---|
| 23 | 15.2 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 15.4 |
|---|
| 1 | 15.5 |
|---|
| 2 | 15.6 |
|---|
| 3 | 15.8 |
|---|
| 4 | 15.9 |
|---|
| 5 | 16.0 |
|---|
| 6 | 16.1 |
|---|
| 7 | 16.3 |
|---|
| 8 | 16.4 |
|---|
| 9 | 16.5 |
|---|
| 10 | 16.6 |
|---|
| 11 | 16.7 |
|---|
| 12 | 16.9 |
|---|
| 13 | 17.0 |
|---|
| 14 | 17.1 |
|---|
| 15 | 17.2 |
|---|
| 16 | 17.3 |
|---|
| 17 | 17.4 |
|---|
| 18 | 17.5 |
|---|
| 19 | 17.6 |
|---|
| 20 | 17.7 |
|---|
| 21 | 17.8 |
|---|
| 22 | 17.9 |
|---|
| 23 | 18.0 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.1 |
|---|
| 1 | 18.2 |
|---|
| 2 | 18.3 |
|---|
| 3 | 18.4 |
|---|
| 4 | 18.5 |
|---|
| 5 | 18.6 |
|---|
| 6 | 18.7 |
|---|
| 7 | 18.8 |
|---|
| 8 | 18.9 |
|---|
| 9 | 19.0 |
|---|
| 10 | 19.0 |
|---|
| 11 | 19.1 |
|---|
| 12 | 19.2 |
|---|
| 13 | 19.3 |
|---|
| 14 | 19.4 |
|---|
| 15 | 19.4 |
|---|
| 16 | 19.5 |
|---|
| 17 | 19.6 |
|---|
| 18 | 19.7 |
|---|
| 19 | 19.7 |
|---|
| 20 | 19.8 |
|---|
| 21 | 19.9 |
|---|
| 22 | 19.9 |
|---|
| 23 | 20.0 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.0 |
|---|
| 1 | 20.1 |
|---|
| 2 | 20.1 |
|---|
| 3 | 20.1 |
|---|
| 4 | 20.1 |
|---|
| 5 | 20.1 |
|---|
| 6 | 20.1 |
|---|
| 7 | 20.1 |
|---|
| 8 | 20.1 |
|---|
| 9 | 20.1 |
|---|
| 10 | 20.1 |
|---|
| 11 | 20.1 |
|---|
| 12 | 20.1 |
|---|
| 13 | 20.1 |
|---|
| 14 | 20.1 |
|---|
| 15 | 20.1 |
|---|
| 16 | 20.1 |
|---|
| 17 | 20.1 |
|---|
| 18 | 20.1 |
|---|
| 19 | 20.1 |
|---|
| 20 | 20.1 |
|---|
| 21 | 20.1 |
|---|
| 22 | 20.1 |
|---|
| 23 | 20.1 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.2 |
|---|
| 1 | 20.2 |
|---|
| 2 | 20.2 |
|---|
| 3 | 20.2 |
|---|
| 4 | 20.2 |
|---|
| 5 | 20.2 |
|---|
| 6 | 20.2 |
|---|
| 7 | 20.2 |
|---|
| 8 | 20.2 |
|---|
| 9 | 20.2 |
|---|
| 10 | 20.2 |
|---|
| 11 | 20.2 |
|---|
| 12 | 20.2 |
|---|
| 13 | 20.2 |
|---|
| 14 | 20.2 |
|---|
| 15 | 20.2 |
|---|
| 16 | 20.2 |
|---|
| 17 | 20.2 |
|---|
| 18 | 20.2 |
|---|
| 19 | 20.2 |
|---|
| 20 | 20.2 |
|---|
| 21 | 20.2 |
|---|
| 22 | 20.2 |
|---|
| 23 | 20.3 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.3 |
|---|
| 1 | 20.3 |
|---|
| 2 | 20.3 |
|---|
| 3 | 20.3 |
|---|
| 4 | 20.3 |
|---|
| 5 | 20.3 |
|---|
| 6 | 20.3 |
|---|
| 7 | 20.3 |
|---|
| 8 | 20.3 |
|---|
| 9 | 20.3 |
|---|
| 10 | 20.3 |
|---|
| 11 | 20.3 |
|---|
| 12 | 20.3 |
|---|
| 13 | 20.3 |
|---|
| 14 | 20.3 |
|---|
| 15 | 20.3 |
|---|
| 16 | 20.3 |
|---|
| 17 | 20.3 |
|---|
| 18 | 20.3 |
|---|
| 19 | 20.3 |
|---|
| 20 | 20.3 |
|---|
| 21 | 20.3 |
|---|
| 22 | 20.4 |
|---|
| 23 | 20.4 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.4 |
|---|
| 1 | 20.4 |
|---|
| 2 | 20.4 |
|---|
| 3 | 20.4 |
|---|
| 4 | 20.4 |
|---|
| 5 | 20.4 |
|---|
| 6 | 20.4 |
|---|
| 7 | 20.4 |
|---|
| 8 | 20.4 |
|---|
| 9 | 20.4 |
|---|
| 10 | 20.4 |
|---|
| 11 | 20.4 |
|---|
| 12 | 20.4 |
|---|
| 13 | 20.4 |
|---|
| 14 | 20.4 |
|---|
| 15 | 20.4 |
|---|
| 16 | 20.4 |
|---|
| 17 | 20.4 |
|---|
| 18 | 20.4 |
|---|
| 19 | 20.4 |
|---|
| 20 | 20.4 |
|---|
| 21 | 20.5 |
|---|
| 22 | 20.5 |
|---|
| 23 | 20.5 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.5 |
|---|
| 1 | 20.5 |
|---|
| 2 | 20.5 |
|---|
| 3 | 20.5 |
|---|
| 4 | 20.5 |
|---|
| 5 | 20.5 |
|---|
| 6 | 20.5 |
|---|
| 7 | 20.5 |
|---|
| 8 | 20.5 |
|---|
| 9 | 20.5 |
|---|
| 10 | 20.5 |
|---|
| 11 | 20.5 |
|---|
| 12 | 20.5 |
|---|
| 13 | 20.5 |
|---|
| 14 | 20.5 |
|---|
| 15 | 20.5 |
|---|
| 16 | 20.5 |
|---|
| 17 | 20.5 |
|---|
| 18 | 20.5 |
|---|
| 19 | 20.5 |
|---|
| 20 | 20.5 |
|---|
| 21 | 20.6 |
|---|
| 22 | 20.6 |
|---|
| 23 | 20.6 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.6 |
|---|
| 1 | 20.6 |
|---|
| 2 | 20.6 |
|---|
| 3 | 20.6 |
|---|
| 4 | 20.6 |
|---|
| 5 | 20.6 |
|---|
| 6 | 20.6 |
|---|
| 7 | 20.6 |
|---|
| 8 | 20.6 |
|---|
| 9 | 20.6 |
|---|
| 10 | 20.6 |
|---|
| 11 | 20.6 |
|---|
| 12 | 20.6 |
|---|
| 13 | 20.6 |
|---|
| 14 | 20.6 |
|---|
| 15 | 20.6 |
|---|
| 16 | 20.6 |
|---|
| 17 | 20.6 |
|---|
| 18 | 20.6 |
|---|
| 19 | 20.6 |
|---|
| 20 | 20.7 |
|---|
| 21 | 20.7 |
|---|
| 22 | 20.7 |
|---|
| 23 | 20.7 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.7 |
|---|
| 1 | 20.7 |
|---|
| 2 | 20.7 |
|---|
| 3 | 20.7 |
|---|
| 4 | 20.7 |
|---|
| 5 | 20.7 |
|---|
| 6 | 20.7 |
|---|
| 7 | 20.7 |
|---|
| 8 | 20.7 |
|---|
| 9 | 20.7 |
|---|
| 10 | 20.7 |
|---|
| 11 | 20.7 |
|---|
| 12 | 20.7 |
|---|
| 13 | 20.7 |
|---|
| 14 | 20.7 |
|---|
| 15 | 20.7 |
|---|
| 16 | 20.7 |
|---|
| 17 | 20.7 |
|---|
| 18 | 20.7 |
|---|
| 19 | 20.8 |
|---|
| 20 | 20.8 |
|---|
| 21 | 20.8 |
|---|
| 22 | 20.8 |
|---|
| 23 | 20.8 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.8 |
|---|
| 1 | 20.8 |
|---|
| 2 | 20.8 |
|---|
| 3 | 20.8 |
|---|
| 4 | 20.8 |
|---|
| 5 | 20.8 |
|---|
| 6 | 20.8 |
|---|
| 7 | 20.8 |
|---|
| 8 | 20.8 |
|---|
| 9 | 20.8 |
|---|
| 10 | 20.8 |
|---|
| 11 | 20.8 |
|---|
| 12 | 20.8 |
|---|
| 13 | 20.8 |
|---|
| 14 | 20.8 |
|---|
| 15 | 20.8 |
|---|
| 16 | 20.8 |
|---|
| 17 | 20.8 |
|---|
| 18 | 20.8 |
|---|
| 19 | 20.9 |
|---|
| 20 | 20.9 |
|---|
| 21 | 20.9 |
|---|
| 22 | 20.9 |
|---|
| 23 | 20.9 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.9 |
|---|
| 1 | 20.9 |
|---|
| 2 | 20.9 |
|---|
| 3 | 20.9 |
|---|
| 4 | 20.9 |
|---|
| 5 | 20.9 |
|---|
| 6 | 20.9 |
|---|
| 7 | 20.9 |
|---|
| 8 | 20.9 |
|---|
| 9 | 20.9 |
|---|
| 10 | 20.9 |
|---|
| 11 | 20.9 |
|---|
| 12 | 20.9 |
|---|
| 13 | 20.9 |
|---|
| 14 | 20.9 |
|---|
| 15 | 20.9 |
|---|
| 16 | 20.9 |
|---|
| 17 | 20.9 |
|---|
| 18 | 21.0 |
|---|
| 19 | 21.0 |
|---|
| 20 | 21.0 |
|---|
| 21 | 21.0 |
|---|
| 22 | 21.0 |
|---|
| 23 | 21.0 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.0 |
|---|
| 1 | 21.0 |
|---|
| 2 | 21.0 |
|---|
| 3 | 21.0 |
|---|
| 4 | 21.0 |
|---|
| 5 | 21.0 |
|---|
| 6 | 21.0 |
|---|
| 7 | 21.0 |
|---|
| 8 | 21.0 |
|---|
| 9 | 21.0 |
|---|
| 10 | 21.0 |
|---|
| 11 | 21.0 |
|---|
| 12 | 21.0 |
|---|
| 13 | 21.0 |
|---|
| 14 | 21.0 |
|---|
| 15 | 21.0 |
|---|
| 16 | 21.0 |
|---|
| 17 | 21.0 |
|---|
| 18 | 21.1 |
|---|
| 19 | 21.1 |
|---|
| 20 | 21.1 |
|---|
| 21 | 21.1 |
|---|
| 22 | 21.1 |
|---|
| 23 | 21.1 |
|---|
Completed day 14
AAP 2022 · Phototherapy · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.1 |
|---|
| 1 | 21.1 |
|---|
| 2 | 21.1 |
|---|
| 3 | 21.1 |
|---|
| 4 | 21.1 |
|---|
| 5 | 21.1 |
|---|
| 6 | 21.1 |
|---|
| 7 | 21.1 |
|---|
| 8 | 21.1 |
|---|
| 9 | 21.1 |
|---|
| 10 | 21.1 |
|---|
| 11 | 21.1 |
|---|
| 12 | 21.1 |
|---|
| 13 | 21.1 |
|---|
| 14 | 21.1 |
|---|
| 15 | 21.1 |
|---|
| 16 | 21.1 |
|---|
| 17 | 21.1 |
|---|
| 18 | 21.1 |
|---|
| 19 | 21.1 |
|---|
| 20 | 21.1 |
|---|
| 21 | 21.1 |
|---|
| 22 | 21.1 |
|---|
| 23 | 21.1 |
|---|
AAP 2022 · Supplemental Table 1, PDF p21 →
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 6.9 |
|---|
| 2 | 7.1 |
|---|
| 3 | 7.3 |
|---|
| 4 | 7.5 |
|---|
| 5 | 7.7 |
|---|
| 6 | 7.9 |
|---|
| 7 | 8.1 |
|---|
| 8 | 8.3 |
|---|
| 9 | 8.5 |
|---|
| 10 | 8.7 |
|---|
| 11 | 8.8 |
|---|
| 12 | 9.0 |
|---|
| 13 | 9.2 |
|---|
| 14 | 9.4 |
|---|
| 15 | 9.6 |
|---|
| 16 | 9.8 |
|---|
| 17 | 9.9 |
|---|
| 18 | 10.1 |
|---|
| 19 | 10.3 |
|---|
| 20 | 10.5 |
|---|
| 21 | 10.6 |
|---|
| 22 | 10.8 |
|---|
| 23 | 11.0 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 11.2 |
|---|
| 1 | 11.3 |
|---|
| 2 | 11.5 |
|---|
| 3 | 11.7 |
|---|
| 4 | 11.8 |
|---|
| 5 | 12.0 |
|---|
| 6 | 12.1 |
|---|
| 7 | 12.3 |
|---|
| 8 | 12.5 |
|---|
| 9 | 12.6 |
|---|
| 10 | 12.8 |
|---|
| 11 | 12.9 |
|---|
| 12 | 13.1 |
|---|
| 13 | 13.2 |
|---|
| 14 | 13.4 |
|---|
| 15 | 13.5 |
|---|
| 16 | 13.7 |
|---|
| 17 | 13.8 |
|---|
| 18 | 13.9 |
|---|
| 19 | 14.1 |
|---|
| 20 | 14.2 |
|---|
| 21 | 14.4 |
|---|
| 22 | 14.5 |
|---|
| 23 | 14.6 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 14.8 |
|---|
| 1 | 14.9 |
|---|
| 2 | 15.0 |
|---|
| 3 | 15.1 |
|---|
| 4 | 15.3 |
|---|
| 5 | 15.4 |
|---|
| 6 | 15.5 |
|---|
| 7 | 15.6 |
|---|
| 8 | 15.8 |
|---|
| 9 | 15.9 |
|---|
| 10 | 16.0 |
|---|
| 11 | 16.1 |
|---|
| 12 | 16.2 |
|---|
| 13 | 16.3 |
|---|
| 14 | 16.5 |
|---|
| 15 | 16.6 |
|---|
| 16 | 16.7 |
|---|
| 17 | 16.8 |
|---|
| 18 | 16.9 |
|---|
| 19 | 17.0 |
|---|
| 20 | 17.1 |
|---|
| 21 | 17.2 |
|---|
| 22 | 17.3 |
|---|
| 23 | 17.4 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.5 |
|---|
| 1 | 17.6 |
|---|
| 2 | 17.7 |
|---|
| 3 | 17.8 |
|---|
| 4 | 17.9 |
|---|
| 5 | 17.9 |
|---|
| 6 | 18.0 |
|---|
| 7 | 18.1 |
|---|
| 8 | 18.2 |
|---|
| 9 | 18.3 |
|---|
| 10 | 18.4 |
|---|
| 11 | 18.4 |
|---|
| 12 | 18.5 |
|---|
| 13 | 18.6 |
|---|
| 14 | 18.7 |
|---|
| 15 | 18.8 |
|---|
| 16 | 18.8 |
|---|
| 17 | 18.9 |
|---|
| 18 | 19.0 |
|---|
| 19 | 19.0 |
|---|
| 20 | 19.1 |
|---|
| 21 | 19.2 |
|---|
| 22 | 19.2 |
|---|
| 23 | 19.3 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.3 |
|---|
| 1 | 19.3 |
|---|
| 2 | 19.3 |
|---|
| 3 | 19.3 |
|---|
| 4 | 19.3 |
|---|
| 5 | 19.4 |
|---|
| 6 | 19.4 |
|---|
| 7 | 19.4 |
|---|
| 8 | 19.4 |
|---|
| 9 | 19.4 |
|---|
| 10 | 19.4 |
|---|
| 11 | 19.4 |
|---|
| 12 | 19.4 |
|---|
| 13 | 19.4 |
|---|
| 14 | 19.4 |
|---|
| 15 | 19.4 |
|---|
| 16 | 19.4 |
|---|
| 17 | 19.4 |
|---|
| 18 | 19.4 |
|---|
| 19 | 19.4 |
|---|
| 20 | 19.4 |
|---|
| 21 | 19.4 |
|---|
| 22 | 19.4 |
|---|
| 23 | 19.4 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.4 |
|---|
| 1 | 19.4 |
|---|
| 2 | 19.4 |
|---|
| 3 | 19.4 |
|---|
| 4 | 19.5 |
|---|
| 5 | 19.5 |
|---|
| 6 | 19.5 |
|---|
| 7 | 19.5 |
|---|
| 8 | 19.5 |
|---|
| 9 | 19.5 |
|---|
| 10 | 19.5 |
|---|
| 11 | 19.5 |
|---|
| 12 | 19.5 |
|---|
| 13 | 19.5 |
|---|
| 14 | 19.5 |
|---|
| 15 | 19.5 |
|---|
| 16 | 19.5 |
|---|
| 17 | 19.5 |
|---|
| 18 | 19.5 |
|---|
| 19 | 19.5 |
|---|
| 20 | 19.5 |
|---|
| 21 | 19.5 |
|---|
| 22 | 19.5 |
|---|
| 23 | 19.5 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.5 |
|---|
| 1 | 19.5 |
|---|
| 2 | 19.5 |
|---|
| 3 | 19.6 |
|---|
| 4 | 19.6 |
|---|
| 5 | 19.6 |
|---|
| 6 | 19.6 |
|---|
| 7 | 19.6 |
|---|
| 8 | 19.6 |
|---|
| 9 | 19.6 |
|---|
| 10 | 19.6 |
|---|
| 11 | 19.6 |
|---|
| 12 | 19.6 |
|---|
| 13 | 19.6 |
|---|
| 14 | 19.6 |
|---|
| 15 | 19.6 |
|---|
| 16 | 19.6 |
|---|
| 17 | 19.6 |
|---|
| 18 | 19.6 |
|---|
| 19 | 19.6 |
|---|
| 20 | 19.6 |
|---|
| 21 | 19.6 |
|---|
| 22 | 19.6 |
|---|
| 23 | 19.6 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.6 |
|---|
| 1 | 19.6 |
|---|
| 2 | 19.6 |
|---|
| 3 | 19.7 |
|---|
| 4 | 19.7 |
|---|
| 5 | 19.7 |
|---|
| 6 | 19.7 |
|---|
| 7 | 19.7 |
|---|
| 8 | 19.7 |
|---|
| 9 | 19.7 |
|---|
| 10 | 19.7 |
|---|
| 11 | 19.7 |
|---|
| 12 | 19.7 |
|---|
| 13 | 19.7 |
|---|
| 14 | 19.7 |
|---|
| 15 | 19.7 |
|---|
| 16 | 19.7 |
|---|
| 17 | 19.7 |
|---|
| 18 | 19.7 |
|---|
| 19 | 19.7 |
|---|
| 20 | 19.7 |
|---|
| 21 | 19.7 |
|---|
| 22 | 19.7 |
|---|
| 23 | 19.7 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.7 |
|---|
| 1 | 19.7 |
|---|
| 2 | 19.8 |
|---|
| 3 | 19.8 |
|---|
| 4 | 19.8 |
|---|
| 5 | 19.8 |
|---|
| 6 | 19.8 |
|---|
| 7 | 19.8 |
|---|
| 8 | 19.8 |
|---|
| 9 | 19.8 |
|---|
| 10 | 19.8 |
|---|
| 11 | 19.8 |
|---|
| 12 | 19.8 |
|---|
| 13 | 19.8 |
|---|
| 14 | 19.8 |
|---|
| 15 | 19.8 |
|---|
| 16 | 19.8 |
|---|
| 17 | 19.8 |
|---|
| 18 | 19.8 |
|---|
| 19 | 19.8 |
|---|
| 20 | 19.8 |
|---|
| 21 | 19.8 |
|---|
| 22 | 19.8 |
|---|
| 23 | 19.8 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.8 |
|---|
| 1 | 19.9 |
|---|
| 2 | 19.9 |
|---|
| 3 | 19.9 |
|---|
| 4 | 19.9 |
|---|
| 5 | 19.9 |
|---|
| 6 | 19.9 |
|---|
| 7 | 19.9 |
|---|
| 8 | 19.9 |
|---|
| 9 | 19.9 |
|---|
| 10 | 19.9 |
|---|
| 11 | 19.9 |
|---|
| 12 | 19.9 |
|---|
| 13 | 19.9 |
|---|
| 14 | 19.9 |
|---|
| 15 | 19.9 |
|---|
| 16 | 19.9 |
|---|
| 17 | 19.9 |
|---|
| 18 | 19.9 |
|---|
| 19 | 19.9 |
|---|
| 20 | 19.9 |
|---|
| 21 | 19.9 |
|---|
| 22 | 19.9 |
|---|
| 23 | 19.9 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.9 |
|---|
| 1 | 20.0 |
|---|
| 2 | 20.0 |
|---|
| 3 | 20.0 |
|---|
| 4 | 20.0 |
|---|
| 5 | 20.0 |
|---|
| 6 | 20.0 |
|---|
| 7 | 20.0 |
|---|
| 8 | 20.0 |
|---|
| 9 | 20.0 |
|---|
| 10 | 20.0 |
|---|
| 11 | 20.0 |
|---|
| 12 | 20.0 |
|---|
| 13 | 20.0 |
|---|
| 14 | 20.0 |
|---|
| 15 | 20.0 |
|---|
| 16 | 20.0 |
|---|
| 17 | 20.0 |
|---|
| 18 | 20.0 |
|---|
| 19 | 20.0 |
|---|
| 20 | 20.0 |
|---|
| 21 | 20.0 |
|---|
| 22 | 20.0 |
|---|
| 23 | 20.0 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.1 |
|---|
| 1 | 20.1 |
|---|
| 2 | 20.1 |
|---|
| 3 | 20.1 |
|---|
| 4 | 20.1 |
|---|
| 5 | 20.1 |
|---|
| 6 | 20.1 |
|---|
| 7 | 20.1 |
|---|
| 8 | 20.1 |
|---|
| 9 | 20.1 |
|---|
| 10 | 20.1 |
|---|
| 11 | 20.1 |
|---|
| 12 | 20.1 |
|---|
| 13 | 20.1 |
|---|
| 14 | 20.1 |
|---|
| 15 | 20.1 |
|---|
| 16 | 20.1 |
|---|
| 17 | 20.1 |
|---|
| 18 | 20.1 |
|---|
| 19 | 20.1 |
|---|
| 20 | 20.1 |
|---|
| 21 | 20.1 |
|---|
| 22 | 20.1 |
|---|
| 23 | 20.1 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.2 |
|---|
| 1 | 20.2 |
|---|
| 2 | 20.2 |
|---|
| 3 | 20.2 |
|---|
| 4 | 20.2 |
|---|
| 5 | 20.2 |
|---|
| 6 | 20.2 |
|---|
| 7 | 20.2 |
|---|
| 8 | 20.2 |
|---|
| 9 | 20.2 |
|---|
| 10 | 20.2 |
|---|
| 11 | 20.2 |
|---|
| 12 | 20.2 |
|---|
| 13 | 20.2 |
|---|
| 14 | 20.2 |
|---|
| 15 | 20.2 |
|---|
| 16 | 20.2 |
|---|
| 17 | 20.2 |
|---|
| 18 | 20.2 |
|---|
| 19 | 20.2 |
|---|
| 20 | 20.2 |
|---|
| 21 | 20.2 |
|---|
| 22 | 20.2 |
|---|
| 23 | 20.2 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.3 |
|---|
| 1 | 20.3 |
|---|
| 2 | 20.3 |
|---|
| 3 | 20.3 |
|---|
| 4 | 20.3 |
|---|
| 5 | 20.3 |
|---|
| 6 | 20.3 |
|---|
| 7 | 20.3 |
|---|
| 8 | 20.3 |
|---|
| 9 | 20.3 |
|---|
| 10 | 20.3 |
|---|
| 11 | 20.3 |
|---|
| 12 | 20.3 |
|---|
| 13 | 20.3 |
|---|
| 14 | 20.3 |
|---|
| 15 | 20.3 |
|---|
| 16 | 20.3 |
|---|
| 17 | 20.3 |
|---|
| 18 | 20.3 |
|---|
| 19 | 20.3 |
|---|
| 20 | 20.3 |
|---|
| 21 | 20.3 |
|---|
| 22 | 20.4 |
|---|
| 23 | 20.4 |
|---|
Completed day 14
AAP 2022 · Phototherapy · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.4 |
|---|
| 1 | 20.4 |
|---|
| 2 | 20.4 |
|---|
| 3 | 20.4 |
|---|
| 4 | 20.4 |
|---|
| 5 | 20.4 |
|---|
| 6 | 20.4 |
|---|
| 7 | 20.4 |
|---|
| 8 | 20.4 |
|---|
| 9 | 20.4 |
|---|
| 10 | 20.4 |
|---|
| 11 | 20.4 |
|---|
| 12 | 20.4 |
|---|
| 13 | 20.4 |
|---|
| 14 | 20.4 |
|---|
| 15 | 20.4 |
|---|
| 16 | 20.4 |
|---|
| 17 | 20.4 |
|---|
| 18 | 20.4 |
|---|
| 19 | 20.4 |
|---|
| 20 | 20.4 |
|---|
| 21 | 20.4 |
|---|
| 22 | 20.4 |
|---|
| 23 | 20.4 |
|---|
AAP 2022 · Supplemental Table 1, PDF p21 →
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 6.4 |
|---|
| 2 | 6.6 |
|---|
| 3 | 6.8 |
|---|
| 4 | 7.0 |
|---|
| 5 | 7.2 |
|---|
| 6 | 7.4 |
|---|
| 7 | 7.6 |
|---|
| 8 | 7.8 |
|---|
| 9 | 7.9 |
|---|
| 10 | 8.1 |
|---|
| 11 | 8.3 |
|---|
| 12 | 8.5 |
|---|
| 13 | 8.7 |
|---|
| 14 | 8.9 |
|---|
| 15 | 9.0 |
|---|
| 16 | 9.2 |
|---|
| 17 | 9.4 |
|---|
| 18 | 9.6 |
|---|
| 19 | 9.8 |
|---|
| 20 | 9.9 |
|---|
| 21 | 10.1 |
|---|
| 22 | 10.3 |
|---|
| 23 | 10.4 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 10.6 |
|---|
| 1 | 10.8 |
|---|
| 2 | 10.9 |
|---|
| 3 | 11.1 |
|---|
| 4 | 11.3 |
|---|
| 5 | 11.4 |
|---|
| 6 | 11.6 |
|---|
| 7 | 11.7 |
|---|
| 8 | 11.9 |
|---|
| 9 | 12.0 |
|---|
| 10 | 12.2 |
|---|
| 11 | 12.3 |
|---|
| 12 | 12.5 |
|---|
| 13 | 12.6 |
|---|
| 14 | 12.8 |
|---|
| 15 | 12.9 |
|---|
| 16 | 13.1 |
|---|
| 17 | 13.2 |
|---|
| 18 | 13.4 |
|---|
| 19 | 13.5 |
|---|
| 20 | 13.6 |
|---|
| 21 | 13.8 |
|---|
| 22 | 13.9 |
|---|
| 23 | 14.0 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 14.2 |
|---|
| 1 | 14.3 |
|---|
| 2 | 14.4 |
|---|
| 3 | 14.5 |
|---|
| 4 | 14.7 |
|---|
| 5 | 14.8 |
|---|
| 6 | 14.9 |
|---|
| 7 | 15.0 |
|---|
| 8 | 15.1 |
|---|
| 9 | 15.3 |
|---|
| 10 | 15.4 |
|---|
| 11 | 15.5 |
|---|
| 12 | 15.6 |
|---|
| 13 | 15.7 |
|---|
| 14 | 15.8 |
|---|
| 15 | 15.9 |
|---|
| 16 | 16.0 |
|---|
| 17 | 16.1 |
|---|
| 18 | 16.2 |
|---|
| 19 | 16.3 |
|---|
| 20 | 16.4 |
|---|
| 21 | 16.5 |
|---|
| 22 | 16.6 |
|---|
| 23 | 16.7 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.8 |
|---|
| 1 | 16.9 |
|---|
| 2 | 17.0 |
|---|
| 3 | 17.1 |
|---|
| 4 | 17.2 |
|---|
| 5 | 17.3 |
|---|
| 6 | 17.4 |
|---|
| 7 | 17.5 |
|---|
| 8 | 17.5 |
|---|
| 9 | 17.6 |
|---|
| 10 | 17.7 |
|---|
| 11 | 17.8 |
|---|
| 12 | 17.8 |
|---|
| 13 | 17.9 |
|---|
| 14 | 18.0 |
|---|
| 15 | 18.1 |
|---|
| 16 | 18.1 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.3 |
|---|
| 19 | 18.3 |
|---|
| 20 | 18.4 |
|---|
| 21 | 18.5 |
|---|
| 22 | 18.5 |
|---|
| 23 | 18.6 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.6 |
|---|
| 1 | 18.6 |
|---|
| 2 | 18.6 |
|---|
| 3 | 18.6 |
|---|
| 4 | 18.6 |
|---|
| 5 | 18.6 |
|---|
| 6 | 18.6 |
|---|
| 7 | 18.6 |
|---|
| 8 | 18.6 |
|---|
| 9 | 18.6 |
|---|
| 10 | 18.7 |
|---|
| 11 | 18.7 |
|---|
| 12 | 18.7 |
|---|
| 13 | 18.7 |
|---|
| 14 | 18.7 |
|---|
| 15 | 18.7 |
|---|
| 16 | 18.7 |
|---|
| 17 | 18.7 |
|---|
| 18 | 18.7 |
|---|
| 19 | 18.7 |
|---|
| 20 | 18.7 |
|---|
| 21 | 18.7 |
|---|
| 22 | 18.7 |
|---|
| 23 | 18.7 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.7 |
|---|
| 1 | 18.7 |
|---|
| 2 | 18.7 |
|---|
| 3 | 18.7 |
|---|
| 4 | 18.7 |
|---|
| 5 | 18.7 |
|---|
| 6 | 18.7 |
|---|
| 7 | 18.7 |
|---|
| 8 | 18.7 |
|---|
| 9 | 18.8 |
|---|
| 10 | 18.8 |
|---|
| 11 | 18.8 |
|---|
| 12 | 18.8 |
|---|
| 13 | 18.8 |
|---|
| 14 | 18.8 |
|---|
| 15 | 18.8 |
|---|
| 16 | 18.8 |
|---|
| 17 | 18.8 |
|---|
| 18 | 18.8 |
|---|
| 19 | 18.8 |
|---|
| 20 | 18.8 |
|---|
| 21 | 18.8 |
|---|
| 22 | 18.8 |
|---|
| 23 | 18.8 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.8 |
|---|
| 1 | 18.8 |
|---|
| 2 | 18.8 |
|---|
| 3 | 18.8 |
|---|
| 4 | 18.8 |
|---|
| 5 | 18.8 |
|---|
| 6 | 18.8 |
|---|
| 7 | 18.8 |
|---|
| 8 | 18.9 |
|---|
| 9 | 18.9 |
|---|
| 10 | 18.9 |
|---|
| 11 | 18.9 |
|---|
| 12 | 18.9 |
|---|
| 13 | 18.9 |
|---|
| 14 | 18.9 |
|---|
| 15 | 18.9 |
|---|
| 16 | 18.9 |
|---|
| 17 | 18.9 |
|---|
| 18 | 18.9 |
|---|
| 19 | 18.9 |
|---|
| 20 | 18.9 |
|---|
| 21 | 18.9 |
|---|
| 22 | 18.9 |
|---|
| 23 | 18.9 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.9 |
|---|
| 1 | 18.9 |
|---|
| 2 | 18.9 |
|---|
| 3 | 18.9 |
|---|
| 4 | 18.9 |
|---|
| 5 | 18.9 |
|---|
| 6 | 18.9 |
|---|
| 7 | 19.0 |
|---|
| 8 | 19.0 |
|---|
| 9 | 19.0 |
|---|
| 10 | 19.0 |
|---|
| 11 | 19.0 |
|---|
| 12 | 19.0 |
|---|
| 13 | 19.0 |
|---|
| 14 | 19.0 |
|---|
| 15 | 19.0 |
|---|
| 16 | 19.0 |
|---|
| 17 | 19.0 |
|---|
| 18 | 19.0 |
|---|
| 19 | 19.0 |
|---|
| 20 | 19.0 |
|---|
| 21 | 19.0 |
|---|
| 22 | 19.0 |
|---|
| 23 | 19.0 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.0 |
|---|
| 1 | 19.0 |
|---|
| 2 | 19.0 |
|---|
| 3 | 19.0 |
|---|
| 4 | 19.0 |
|---|
| 5 | 19.0 |
|---|
| 6 | 19.0 |
|---|
| 7 | 19.1 |
|---|
| 8 | 19.1 |
|---|
| 9 | 19.1 |
|---|
| 10 | 19.1 |
|---|
| 11 | 19.1 |
|---|
| 12 | 19.1 |
|---|
| 13 | 19.1 |
|---|
| 14 | 19.1 |
|---|
| 15 | 19.1 |
|---|
| 16 | 19.1 |
|---|
| 17 | 19.1 |
|---|
| 18 | 19.1 |
|---|
| 19 | 19.1 |
|---|
| 20 | 19.1 |
|---|
| 21 | 19.1 |
|---|
| 22 | 19.1 |
|---|
| 23 | 19.1 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.1 |
|---|
| 1 | 19.1 |
|---|
| 2 | 19.1 |
|---|
| 3 | 19.1 |
|---|
| 4 | 19.1 |
|---|
| 5 | 19.1 |
|---|
| 6 | 19.2 |
|---|
| 7 | 19.2 |
|---|
| 8 | 19.2 |
|---|
| 9 | 19.2 |
|---|
| 10 | 19.2 |
|---|
| 11 | 19.2 |
|---|
| 12 | 19.2 |
|---|
| 13 | 19.2 |
|---|
| 14 | 19.2 |
|---|
| 15 | 19.2 |
|---|
| 16 | 19.2 |
|---|
| 17 | 19.2 |
|---|
| 18 | 19.2 |
|---|
| 19 | 19.2 |
|---|
| 20 | 19.2 |
|---|
| 21 | 19.2 |
|---|
| 22 | 19.2 |
|---|
| 23 | 19.2 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.2 |
|---|
| 1 | 19.2 |
|---|
| 2 | 19.2 |
|---|
| 3 | 19.2 |
|---|
| 4 | 19.2 |
|---|
| 5 | 19.3 |
|---|
| 6 | 19.3 |
|---|
| 7 | 19.3 |
|---|
| 8 | 19.3 |
|---|
| 9 | 19.3 |
|---|
| 10 | 19.3 |
|---|
| 11 | 19.3 |
|---|
| 12 | 19.3 |
|---|
| 13 | 19.3 |
|---|
| 14 | 19.3 |
|---|
| 15 | 19.3 |
|---|
| 16 | 19.3 |
|---|
| 17 | 19.3 |
|---|
| 18 | 19.3 |
|---|
| 19 | 19.3 |
|---|
| 20 | 19.3 |
|---|
| 21 | 19.3 |
|---|
| 22 | 19.3 |
|---|
| 23 | 19.3 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.3 |
|---|
| 1 | 19.3 |
|---|
| 2 | 19.3 |
|---|
| 3 | 19.3 |
|---|
| 4 | 19.3 |
|---|
| 5 | 19.4 |
|---|
| 6 | 19.4 |
|---|
| 7 | 19.4 |
|---|
| 8 | 19.4 |
|---|
| 9 | 19.4 |
|---|
| 10 | 19.4 |
|---|
| 11 | 19.4 |
|---|
| 12 | 19.4 |
|---|
| 13 | 19.4 |
|---|
| 14 | 19.4 |
|---|
| 15 | 19.4 |
|---|
| 16 | 19.4 |
|---|
| 17 | 19.4 |
|---|
| 18 | 19.4 |
|---|
| 19 | 19.4 |
|---|
| 20 | 19.4 |
|---|
| 21 | 19.4 |
|---|
| 22 | 19.4 |
|---|
| 23 | 19.4 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.4 |
|---|
| 1 | 19.4 |
|---|
| 2 | 19.4 |
|---|
| 3 | 19.4 |
|---|
| 4 | 19.5 |
|---|
| 5 | 19.5 |
|---|
| 6 | 19.5 |
|---|
| 7 | 19.5 |
|---|
| 8 | 19.5 |
|---|
| 9 | 19.5 |
|---|
| 10 | 19.5 |
|---|
| 11 | 19.5 |
|---|
| 12 | 19.5 |
|---|
| 13 | 19.5 |
|---|
| 14 | 19.5 |
|---|
| 15 | 19.5 |
|---|
| 16 | 19.5 |
|---|
| 17 | 19.5 |
|---|
| 18 | 19.5 |
|---|
| 19 | 19.5 |
|---|
| 20 | 19.5 |
|---|
| 21 | 19.5 |
|---|
| 22 | 19.5 |
|---|
| 23 | 19.5 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.5 |
|---|
| 1 | 19.5 |
|---|
| 2 | 19.5 |
|---|
| 3 | 19.5 |
|---|
| 4 | 19.6 |
|---|
| 5 | 19.6 |
|---|
| 6 | 19.6 |
|---|
| 7 | 19.6 |
|---|
| 8 | 19.6 |
|---|
| 9 | 19.6 |
|---|
| 10 | 19.6 |
|---|
| 11 | 19.6 |
|---|
| 12 | 19.6 |
|---|
| 13 | 19.6 |
|---|
| 14 | 19.6 |
|---|
| 15 | 19.6 |
|---|
| 16 | 19.6 |
|---|
| 17 | 19.6 |
|---|
| 18 | 19.6 |
|---|
| 19 | 19.6 |
|---|
| 20 | 19.6 |
|---|
| 21 | 19.6 |
|---|
| 22 | 19.6 |
|---|
| 23 | 19.6 |
|---|
Completed day 14
AAP 2022 · Phototherapy · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.6 |
|---|
| 1 | 19.6 |
|---|
| 2 | 19.6 |
|---|
| 3 | 19.6 |
|---|
| 4 | 19.6 |
|---|
| 5 | 19.6 |
|---|
| 6 | 19.6 |
|---|
| 7 | 19.6 |
|---|
| 8 | 19.6 |
|---|
| 9 | 19.6 |
|---|
| 10 | 19.6 |
|---|
| 11 | 19.6 |
|---|
| 12 | 19.6 |
|---|
| 13 | 19.6 |
|---|
| 14 | 19.6 |
|---|
| 15 | 19.6 |
|---|
| 16 | 19.6 |
|---|
| 17 | 19.6 |
|---|
| 18 | 19.6 |
|---|
| 19 | 19.6 |
|---|
| 20 | 19.6 |
|---|
| 21 | 19.6 |
|---|
| 22 | 19.6 |
|---|
| 23 | 19.6 |
|---|
AAP 2022 · Supplemental Table 1, PDF p22 →
Phototherapy · additional neurotoxicity risk(s)
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥96 h (eg, 4 completed days) after birth is 18.2 mg/dL.
Completed day 0
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 6.4 |
|---|
| 2 | 6.6 |
|---|
| 3 | 6.8 |
|---|
| 4 | 7.0 |
|---|
| 5 | 7.2 |
|---|
| 6 | 7.3 |
|---|
| 7 | 7.5 |
|---|
| 8 | 7.7 |
|---|
| 9 | 7.9 |
|---|
| 10 | 8.1 |
|---|
| 11 | 8.3 |
|---|
| 12 | 8.5 |
|---|
| 13 | 8.6 |
|---|
| 14 | 8.8 |
|---|
| 15 | 9.0 |
|---|
| 16 | 9.2 |
|---|
| 17 | 9.4 |
|---|
| 18 | 9.5 |
|---|
| 19 | 9.7 |
|---|
| 20 | 9.9 |
|---|
| 21 | 10.0 |
|---|
| 22 | 10.2 |
|---|
| 23 | 10.4 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 10.5 |
|---|
| 1 | 10.7 |
|---|
| 2 | 10.8 |
|---|
| 3 | 11.0 |
|---|
| 4 | 11.2 |
|---|
| 5 | 11.3 |
|---|
| 6 | 11.5 |
|---|
| 7 | 11.6 |
|---|
| 8 | 11.8 |
|---|
| 9 | 11.9 |
|---|
| 10 | 12.1 |
|---|
| 11 | 12.2 |
|---|
| 12 | 12.4 |
|---|
| 13 | 12.5 |
|---|
| 14 | 12.7 |
|---|
| 15 | 12.8 |
|---|
| 16 | 12.9 |
|---|
| 17 | 13.1 |
|---|
| 18 | 13.2 |
|---|
| 19 | 13.3 |
|---|
| 20 | 13.5 |
|---|
| 21 | 13.6 |
|---|
| 22 | 13.7 |
|---|
| 23 | 13.9 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 14.0 |
|---|
| 1 | 14.1 |
|---|
| 2 | 14.2 |
|---|
| 3 | 14.4 |
|---|
| 4 | 14.5 |
|---|
| 5 | 14.6 |
|---|
| 6 | 14.7 |
|---|
| 7 | 14.8 |
|---|
| 8 | 14.9 |
|---|
| 9 | 15.1 |
|---|
| 10 | 15.2 |
|---|
| 11 | 15.3 |
|---|
| 12 | 15.4 |
|---|
| 13 | 15.5 |
|---|
| 14 | 15.6 |
|---|
| 15 | 15.7 |
|---|
| 16 | 15.8 |
|---|
| 17 | 15.9 |
|---|
| 18 | 16.0 |
|---|
| 19 | 16.1 |
|---|
| 20 | 16.2 |
|---|
| 21 | 16.3 |
|---|
| 22 | 16.4 |
|---|
| 23 | 16.5 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.6 |
|---|
| 1 | 16.6 |
|---|
| 2 | 16.7 |
|---|
| 3 | 16.8 |
|---|
| 4 | 16.9 |
|---|
| 5 | 17.0 |
|---|
| 6 | 17.1 |
|---|
| 7 | 17.1 |
|---|
| 8 | 17.2 |
|---|
| 9 | 17.3 |
|---|
| 10 | 17.4 |
|---|
| 11 | 17.4 |
|---|
| 12 | 17.5 |
|---|
| 13 | 17.6 |
|---|
| 14 | 17.6 |
|---|
| 15 | 17.7 |
|---|
| 16 | 17.8 |
|---|
| 17 | 17.8 |
|---|
| 18 | 17.9 |
|---|
| 19 | 18.0 |
|---|
| 20 | 18.0 |
|---|
| 21 | 18.1 |
|---|
| 22 | 18.1 |
|---|
| 23 | 18.2 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.2 |
|---|
| 1 | 18.2 |
|---|
| 2 | 18.2 |
|---|
| 3 | 18.2 |
|---|
| 4 | 18.2 |
|---|
| 5 | 18.2 |
|---|
| 6 | 18.2 |
|---|
| 7 | 18.2 |
|---|
| 8 | 18.2 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.2 |
|---|
| 11 | 18.2 |
|---|
| 12 | 18.2 |
|---|
| 13 | 18.2 |
|---|
| 14 | 18.2 |
|---|
| 15 | 18.2 |
|---|
| 16 | 18.2 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.2 |
|---|
| 19 | 18.2 |
|---|
| 20 | 18.2 |
|---|
| 21 | 18.2 |
|---|
| 22 | 18.2 |
|---|
| 23 | 18.2 |
|---|
AAP 2022 · Supplemental Table 2, PDF p22 →
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥151 h (eg, 6 completed days and 7 h) after birth is 18.2 mg/dL.
Completed day 0
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 5.9 |
|---|
| 2 | 6.1 |
|---|
| 3 | 6.3 |
|---|
| 4 | 6.5 |
|---|
| 5 | 6.7 |
|---|
| 6 | 6.9 |
|---|
| 7 | 7.0 |
|---|
| 8 | 7.2 |
|---|
| 9 | 7.4 |
|---|
| 10 | 7.6 |
|---|
| 11 | 7.8 |
|---|
| 12 | 8.0 |
|---|
| 13 | 8.1 |
|---|
| 14 | 8.3 |
|---|
| 15 | 8.5 |
|---|
| 16 | 8.7 |
|---|
| 17 | 8.9 |
|---|
| 18 | 9.0 |
|---|
| 19 | 9.2 |
|---|
| 20 | 9.4 |
|---|
| 21 | 9.5 |
|---|
| 22 | 9.7 |
|---|
| 23 | 9.9 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 10.0 |
|---|
| 1 | 10.2 |
|---|
| 2 | 10.4 |
|---|
| 3 | 10.5 |
|---|
| 4 | 10.7 |
|---|
| 5 | 10.8 |
|---|
| 6 | 11.0 |
|---|
| 7 | 11.1 |
|---|
| 8 | 11.3 |
|---|
| 9 | 11.4 |
|---|
| 10 | 11.6 |
|---|
| 11 | 11.7 |
|---|
| 12 | 11.9 |
|---|
| 13 | 12.0 |
|---|
| 14 | 12.2 |
|---|
| 15 | 12.3 |
|---|
| 16 | 12.4 |
|---|
| 17 | 12.6 |
|---|
| 18 | 12.7 |
|---|
| 19 | 12.9 |
|---|
| 20 | 13.0 |
|---|
| 21 | 13.1 |
|---|
| 22 | 13.2 |
|---|
| 23 | 13.4 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 13.5 |
|---|
| 1 | 13.6 |
|---|
| 2 | 13.8 |
|---|
| 3 | 13.9 |
|---|
| 4 | 14.0 |
|---|
| 5 | 14.1 |
|---|
| 6 | 14.2 |
|---|
| 7 | 14.4 |
|---|
| 8 | 14.5 |
|---|
| 9 | 14.6 |
|---|
| 10 | 14.7 |
|---|
| 11 | 14.8 |
|---|
| 12 | 14.9 |
|---|
| 13 | 15.0 |
|---|
| 14 | 15.1 |
|---|
| 15 | 15.2 |
|---|
| 16 | 15.3 |
|---|
| 17 | 15.4 |
|---|
| 18 | 15.5 |
|---|
| 19 | 15.6 |
|---|
| 20 | 15.7 |
|---|
| 21 | 15.8 |
|---|
| 22 | 15.9 |
|---|
| 23 | 16.0 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.1 |
|---|
| 1 | 16.2 |
|---|
| 2 | 16.3 |
|---|
| 3 | 16.4 |
|---|
| 4 | 16.5 |
|---|
| 5 | 16.6 |
|---|
| 6 | 16.6 |
|---|
| 7 | 16.7 |
|---|
| 8 | 16.8 |
|---|
| 9 | 16.9 |
|---|
| 10 | 17.0 |
|---|
| 11 | 17.0 |
|---|
| 12 | 17.1 |
|---|
| 13 | 17.2 |
|---|
| 14 | 17.2 |
|---|
| 15 | 17.3 |
|---|
| 16 | 17.4 |
|---|
| 17 | 17.4 |
|---|
| 18 | 17.5 |
|---|
| 19 | 17.6 |
|---|
| 20 | 17.6 |
|---|
| 21 | 17.7 |
|---|
| 22 | 17.8 |
|---|
| 23 | 17.8 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.9 |
|---|
| 1 | 17.9 |
|---|
| 2 | 17.9 |
|---|
| 3 | 17.9 |
|---|
| 4 | 17.9 |
|---|
| 5 | 17.9 |
|---|
| 6 | 17.9 |
|---|
| 7 | 17.9 |
|---|
| 8 | 17.9 |
|---|
| 9 | 17.9 |
|---|
| 10 | 17.9 |
|---|
| 11 | 17.9 |
|---|
| 12 | 17.9 |
|---|
| 13 | 17.9 |
|---|
| 14 | 17.9 |
|---|
| 15 | 17.9 |
|---|
| 16 | 18.0 |
|---|
| 17 | 18.0 |
|---|
| 18 | 18.0 |
|---|
| 19 | 18.0 |
|---|
| 20 | 18.0 |
|---|
| 21 | 18.0 |
|---|
| 22 | 18.0 |
|---|
| 23 | 18.0 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.0 |
|---|
| 1 | 18.0 |
|---|
| 2 | 18.0 |
|---|
| 3 | 18.0 |
|---|
| 4 | 18.0 |
|---|
| 5 | 18.0 |
|---|
| 6 | 18.0 |
|---|
| 7 | 18.0 |
|---|
| 8 | 18.0 |
|---|
| 9 | 18.0 |
|---|
| 10 | 18.0 |
|---|
| 11 | 18.1 |
|---|
| 12 | 18.1 |
|---|
| 13 | 18.1 |
|---|
| 14 | 18.1 |
|---|
| 15 | 18.1 |
|---|
| 16 | 18.1 |
|---|
| 17 | 18.1 |
|---|
| 18 | 18.1 |
|---|
| 19 | 18.1 |
|---|
| 20 | 18.1 |
|---|
| 21 | 18.1 |
|---|
| 22 | 18.1 |
|---|
| 23 | 18.1 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.1 |
|---|
| 1 | 18.1 |
|---|
| 2 | 18.1 |
|---|
| 3 | 18.1 |
|---|
| 4 | 18.1 |
|---|
| 5 | 18.1 |
|---|
| 6 | 18.1 |
|---|
| 7 | 18.2 |
|---|
| 8 | 18.2 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.2 |
|---|
| 11 | 18.2 |
|---|
| 12 | 18.2 |
|---|
| 13 | 18.2 |
|---|
| 14 | 18.2 |
|---|
| 15 | 18.2 |
|---|
| 16 | 18.2 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.2 |
|---|
| 19 | 18.2 |
|---|
| 20 | 18.2 |
|---|
| 21 | 18.2 |
|---|
| 22 | 18.2 |
|---|
| 23 | 18.2 |
|---|
AAP 2022 · Supplemental Table 2, PDF p22 →
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 5.4 |
|---|
| 2 | 5.6 |
|---|
| 3 | 5.8 |
|---|
| 4 | 6.0 |
|---|
| 5 | 6.2 |
|---|
| 6 | 6.3 |
|---|
| 7 | 6.5 |
|---|
| 8 | 6.7 |
|---|
| 9 | 6.9 |
|---|
| 10 | 7.1 |
|---|
| 11 | 7.3 |
|---|
| 12 | 7.4 |
|---|
| 13 | 7.6 |
|---|
| 14 | 7.8 |
|---|
| 15 | 8.0 |
|---|
| 16 | 8.1 |
|---|
| 17 | 8.3 |
|---|
| 18 | 8.5 |
|---|
| 19 | 8.6 |
|---|
| 20 | 8.8 |
|---|
| 21 | 9.0 |
|---|
| 22 | 9.1 |
|---|
| 23 | 9.3 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 9.4 |
|---|
| 1 | 9.6 |
|---|
| 2 | 9.8 |
|---|
| 3 | 9.9 |
|---|
| 4 | 10.1 |
|---|
| 5 | 10.2 |
|---|
| 6 | 10.4 |
|---|
| 7 | 10.5 |
|---|
| 8 | 10.7 |
|---|
| 9 | 10.8 |
|---|
| 10 | 11.0 |
|---|
| 11 | 11.1 |
|---|
| 12 | 11.2 |
|---|
| 13 | 11.4 |
|---|
| 14 | 11.5 |
|---|
| 15 | 11.7 |
|---|
| 16 | 11.8 |
|---|
| 17 | 11.9 |
|---|
| 18 | 12.1 |
|---|
| 19 | 12.2 |
|---|
| 20 | 12.3 |
|---|
| 21 | 12.5 |
|---|
| 22 | 12.6 |
|---|
| 23 | 12.7 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 12.8 |
|---|
| 1 | 13.0 |
|---|
| 2 | 13.1 |
|---|
| 3 | 13.2 |
|---|
| 4 | 13.3 |
|---|
| 5 | 13.4 |
|---|
| 6 | 13.5 |
|---|
| 7 | 13.7 |
|---|
| 8 | 13.8 |
|---|
| 9 | 13.9 |
|---|
| 10 | 14.0 |
|---|
| 11 | 14.1 |
|---|
| 12 | 14.2 |
|---|
| 13 | 14.3 |
|---|
| 14 | 14.4 |
|---|
| 15 | 14.5 |
|---|
| 16 | 14.6 |
|---|
| 17 | 14.7 |
|---|
| 18 | 14.8 |
|---|
| 19 | 14.9 |
|---|
| 20 | 15.0 |
|---|
| 21 | 15.1 |
|---|
| 22 | 15.2 |
|---|
| 23 | 15.3 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 15.4 |
|---|
| 1 | 15.4 |
|---|
| 2 | 15.5 |
|---|
| 3 | 15.6 |
|---|
| 4 | 15.7 |
|---|
| 5 | 15.8 |
|---|
| 6 | 15.8 |
|---|
| 7 | 15.9 |
|---|
| 8 | 16.0 |
|---|
| 9 | 16.1 |
|---|
| 10 | 16.1 |
|---|
| 11 | 16.2 |
|---|
| 12 | 16.3 |
|---|
| 13 | 16.4 |
|---|
| 14 | 16.4 |
|---|
| 15 | 16.5 |
|---|
| 16 | 16.6 |
|---|
| 17 | 16.6 |
|---|
| 18 | 16.7 |
|---|
| 19 | 16.7 |
|---|
| 20 | 16.8 |
|---|
| 21 | 16.8 |
|---|
| 22 | 16.9 |
|---|
| 23 | 17.0 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.0 |
|---|
| 1 | 17.0 |
|---|
| 2 | 17.0 |
|---|
| 3 | 17.0 |
|---|
| 4 | 17.0 |
|---|
| 5 | 17.0 |
|---|
| 6 | 17.0 |
|---|
| 7 | 17.0 |
|---|
| 8 | 17.1 |
|---|
| 9 | 17.1 |
|---|
| 10 | 17.1 |
|---|
| 11 | 17.1 |
|---|
| 12 | 17.1 |
|---|
| 13 | 17.1 |
|---|
| 14 | 17.1 |
|---|
| 15 | 17.1 |
|---|
| 16 | 17.1 |
|---|
| 17 | 17.1 |
|---|
| 18 | 17.1 |
|---|
| 19 | 17.1 |
|---|
| 20 | 17.1 |
|---|
| 21 | 17.1 |
|---|
| 22 | 17.1 |
|---|
| 23 | 17.1 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.1 |
|---|
| 1 | 17.1 |
|---|
| 2 | 17.1 |
|---|
| 3 | 17.1 |
|---|
| 4 | 17.2 |
|---|
| 5 | 17.2 |
|---|
| 6 | 17.2 |
|---|
| 7 | 17.2 |
|---|
| 8 | 17.2 |
|---|
| 9 | 17.2 |
|---|
| 10 | 17.2 |
|---|
| 11 | 17.2 |
|---|
| 12 | 17.2 |
|---|
| 13 | 17.2 |
|---|
| 14 | 17.2 |
|---|
| 15 | 17.2 |
|---|
| 16 | 17.2 |
|---|
| 17 | 17.2 |
|---|
| 18 | 17.2 |
|---|
| 19 | 17.2 |
|---|
| 20 | 17.2 |
|---|
| 21 | 17.2 |
|---|
| 22 | 17.2 |
|---|
| 23 | 17.3 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.3 |
|---|
| 1 | 17.3 |
|---|
| 2 | 17.3 |
|---|
| 3 | 17.3 |
|---|
| 4 | 17.3 |
|---|
| 5 | 17.3 |
|---|
| 6 | 17.3 |
|---|
| 7 | 17.3 |
|---|
| 8 | 17.3 |
|---|
| 9 | 17.3 |
|---|
| 10 | 17.3 |
|---|
| 11 | 17.3 |
|---|
| 12 | 17.3 |
|---|
| 13 | 17.3 |
|---|
| 14 | 17.3 |
|---|
| 15 | 17.3 |
|---|
| 16 | 17.3 |
|---|
| 17 | 17.3 |
|---|
| 18 | 17.3 |
|---|
| 19 | 17.4 |
|---|
| 20 | 17.4 |
|---|
| 21 | 17.4 |
|---|
| 22 | 17.4 |
|---|
| 23 | 17.4 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.4 |
|---|
| 1 | 17.4 |
|---|
| 2 | 17.4 |
|---|
| 3 | 17.4 |
|---|
| 4 | 17.4 |
|---|
| 5 | 17.4 |
|---|
| 6 | 17.4 |
|---|
| 7 | 17.4 |
|---|
| 8 | 17.4 |
|---|
| 9 | 17.4 |
|---|
| 10 | 17.4 |
|---|
| 11 | 17.4 |
|---|
| 12 | 17.4 |
|---|
| 13 | 17.4 |
|---|
| 14 | 17.5 |
|---|
| 15 | 17.5 |
|---|
| 16 | 17.5 |
|---|
| 17 | 17.5 |
|---|
| 18 | 17.5 |
|---|
| 19 | 17.5 |
|---|
| 20 | 17.5 |
|---|
| 21 | 17.5 |
|---|
| 22 | 17.5 |
|---|
| 23 | 17.5 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.5 |
|---|
| 1 | 17.5 |
|---|
| 2 | 17.5 |
|---|
| 3 | 17.5 |
|---|
| 4 | 17.5 |
|---|
| 5 | 17.5 |
|---|
| 6 | 17.5 |
|---|
| 7 | 17.5 |
|---|
| 8 | 17.5 |
|---|
| 9 | 17.5 |
|---|
| 10 | 17.6 |
|---|
| 11 | 17.6 |
|---|
| 12 | 17.6 |
|---|
| 13 | 17.6 |
|---|
| 14 | 17.6 |
|---|
| 15 | 17.6 |
|---|
| 16 | 17.6 |
|---|
| 17 | 17.6 |
|---|
| 18 | 17.6 |
|---|
| 19 | 17.6 |
|---|
| 20 | 17.6 |
|---|
| 21 | 17.6 |
|---|
| 22 | 17.6 |
|---|
| 23 | 17.6 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.6 |
|---|
| 1 | 17.6 |
|---|
| 2 | 17.6 |
|---|
| 3 | 17.6 |
|---|
| 4 | 17.6 |
|---|
| 5 | 17.7 |
|---|
| 6 | 17.7 |
|---|
| 7 | 17.7 |
|---|
| 8 | 17.7 |
|---|
| 9 | 17.7 |
|---|
| 10 | 17.7 |
|---|
| 11 | 17.7 |
|---|
| 12 | 17.7 |
|---|
| 13 | 17.7 |
|---|
| 14 | 17.7 |
|---|
| 15 | 17.7 |
|---|
| 16 | 17.7 |
|---|
| 17 | 17.7 |
|---|
| 18 | 17.7 |
|---|
| 19 | 17.7 |
|---|
| 20 | 17.7 |
|---|
| 21 | 17.7 |
|---|
| 22 | 17.7 |
|---|
| 23 | 17.7 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.7 |
|---|
| 1 | 17.8 |
|---|
| 2 | 17.8 |
|---|
| 3 | 17.8 |
|---|
| 4 | 17.8 |
|---|
| 5 | 17.8 |
|---|
| 6 | 17.8 |
|---|
| 7 | 17.8 |
|---|
| 8 | 17.8 |
|---|
| 9 | 17.8 |
|---|
| 10 | 17.8 |
|---|
| 11 | 17.8 |
|---|
| 12 | 17.8 |
|---|
| 13 | 17.8 |
|---|
| 14 | 17.8 |
|---|
| 15 | 17.8 |
|---|
| 16 | 17.8 |
|---|
| 17 | 17.8 |
|---|
| 18 | 17.8 |
|---|
| 19 | 17.8 |
|---|
| 20 | 17.9 |
|---|
| 21 | 17.9 |
|---|
| 22 | 17.9 |
|---|
| 23 | 17.9 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.9 |
|---|
| 1 | 17.9 |
|---|
| 2 | 17.9 |
|---|
| 3 | 17.9 |
|---|
| 4 | 17.9 |
|---|
| 5 | 17.9 |
|---|
| 6 | 17.9 |
|---|
| 7 | 17.9 |
|---|
| 8 | 17.9 |
|---|
| 9 | 17.9 |
|---|
| 10 | 17.9 |
|---|
| 11 | 17.9 |
|---|
| 12 | 17.9 |
|---|
| 13 | 17.9 |
|---|
| 14 | 17.9 |
|---|
| 15 | 17.9 |
|---|
| 16 | 18.0 |
|---|
| 17 | 18.0 |
|---|
| 18 | 18.0 |
|---|
| 19 | 18.0 |
|---|
| 20 | 18.0 |
|---|
| 21 | 18.0 |
|---|
| 22 | 18.0 |
|---|
| 23 | 18.0 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.0 |
|---|
| 1 | 18.0 |
|---|
| 2 | 18.0 |
|---|
| 3 | 18.0 |
|---|
| 4 | 18.0 |
|---|
| 5 | 18.0 |
|---|
| 6 | 18.0 |
|---|
| 7 | 18.0 |
|---|
| 8 | 18.0 |
|---|
| 9 | 18.0 |
|---|
| 10 | 18.0 |
|---|
| 11 | 18.1 |
|---|
| 12 | 18.1 |
|---|
| 13 | 18.1 |
|---|
| 14 | 18.1 |
|---|
| 15 | 18.1 |
|---|
| 16 | 18.1 |
|---|
| 17 | 18.1 |
|---|
| 18 | 18.1 |
|---|
| 19 | 18.1 |
|---|
| 20 | 18.1 |
|---|
| 21 | 18.1 |
|---|
| 22 | 18.1 |
|---|
| 23 | 18.1 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.1 |
|---|
| 1 | 18.1 |
|---|
| 2 | 18.1 |
|---|
| 3 | 18.1 |
|---|
| 4 | 18.1 |
|---|
| 5 | 18.1 |
|---|
| 6 | 18.1 |
|---|
| 7 | 18.2 |
|---|
| 8 | 18.2 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.2 |
|---|
| 11 | 18.2 |
|---|
| 12 | 18.2 |
|---|
| 13 | 18.2 |
|---|
| 14 | 18.2 |
|---|
| 15 | 18.2 |
|---|
| 16 | 18.2 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.2 |
|---|
| 19 | 18.2 |
|---|
| 20 | 18.2 |
|---|
| 21 | 18.2 |
|---|
| 22 | 18.2 |
|---|
| 23 | 18.2 |
|---|
Completed day 14
AAP 2022 · Phototherapy · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.2 |
|---|
| 1 | 18.2 |
|---|
| 2 | 18.2 |
|---|
| 3 | 18.2 |
|---|
| 4 | 18.2 |
|---|
| 5 | 18.2 |
|---|
| 6 | 18.2 |
|---|
| 7 | 18.2 |
|---|
| 8 | 18.2 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.2 |
|---|
| 11 | 18.2 |
|---|
| 12 | 18.2 |
|---|
| 13 | 18.2 |
|---|
| 14 | 18.2 |
|---|
| 15 | 18.2 |
|---|
| 16 | 18.2 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.2 |
|---|
| 19 | 18.2 |
|---|
| 20 | 18.2 |
|---|
| 21 | 18.2 |
|---|
| 22 | 18.2 |
|---|
| 23 | 18.2 |
|---|
AAP 2022 · Supplemental Table 2, PDF p23 →
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 4.9 |
|---|
| 2 | 5.1 |
|---|
| 3 | 5.3 |
|---|
| 4 | 5.5 |
|---|
| 5 | 5.6 |
|---|
| 6 | 5.8 |
|---|
| 7 | 6.0 |
|---|
| 8 | 6.2 |
|---|
| 9 | 6.4 |
|---|
| 10 | 6.5 |
|---|
| 11 | 6.7 |
|---|
| 12 | 6.9 |
|---|
| 13 | 7.1 |
|---|
| 14 | 7.2 |
|---|
| 15 | 7.4 |
|---|
| 16 | 7.6 |
|---|
| 17 | 7.7 |
|---|
| 18 | 7.9 |
|---|
| 19 | 8.1 |
|---|
| 20 | 8.2 |
|---|
| 21 | 8.4 |
|---|
| 22 | 8.6 |
|---|
| 23 | 8.7 |
|---|
Completed day 1
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 8.9 |
|---|
| 1 | 9.0 |
|---|
| 2 | 9.2 |
|---|
| 3 | 9.3 |
|---|
| 4 | 9.5 |
|---|
| 5 | 9.6 |
|---|
| 6 | 9.8 |
|---|
| 7 | 9.9 |
|---|
| 8 | 10.1 |
|---|
| 9 | 10.2 |
|---|
| 10 | 10.3 |
|---|
| 11 | 10.5 |
|---|
| 12 | 10.6 |
|---|
| 13 | 10.8 |
|---|
| 14 | 10.9 |
|---|
| 15 | 11.0 |
|---|
| 16 | 11.2 |
|---|
| 17 | 11.3 |
|---|
| 18 | 11.4 |
|---|
| 19 | 11.5 |
|---|
| 20 | 11.7 |
|---|
| 21 | 11.8 |
|---|
| 22 | 11.9 |
|---|
| 23 | 12.0 |
|---|
Completed day 2
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 12.2 |
|---|
| 1 | 12.3 |
|---|
| 2 | 12.4 |
|---|
| 3 | 12.5 |
|---|
| 4 | 12.6 |
|---|
| 5 | 12.7 |
|---|
| 6 | 12.8 |
|---|
| 7 | 13.0 |
|---|
| 8 | 13.1 |
|---|
| 9 | 13.2 |
|---|
| 10 | 13.3 |
|---|
| 11 | 13.4 |
|---|
| 12 | 13.5 |
|---|
| 13 | 13.6 |
|---|
| 14 | 13.7 |
|---|
| 15 | 13.8 |
|---|
| 16 | 13.9 |
|---|
| 17 | 14.0 |
|---|
| 18 | 14.1 |
|---|
| 19 | 14.2 |
|---|
| 20 | 14.2 |
|---|
| 21 | 14.3 |
|---|
| 22 | 14.4 |
|---|
| 23 | 14.5 |
|---|
Completed day 3
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 14.6 |
|---|
| 1 | 14.7 |
|---|
| 2 | 14.8 |
|---|
| 3 | 14.8 |
|---|
| 4 | 14.9 |
|---|
| 5 | 15.0 |
|---|
| 6 | 15.1 |
|---|
| 7 | 15.1 |
|---|
| 8 | 15.2 |
|---|
| 9 | 15.3 |
|---|
| 10 | 15.3 |
|---|
| 11 | 15.4 |
|---|
| 12 | 15.5 |
|---|
| 13 | 15.5 |
|---|
| 14 | 15.6 |
|---|
| 15 | 15.7 |
|---|
| 16 | 15.7 |
|---|
| 17 | 15.8 |
|---|
| 18 | 15.8 |
|---|
| 19 | 15.9 |
|---|
| 20 | 15.9 |
|---|
| 21 | 16.0 |
|---|
| 22 | 16.1 |
|---|
| 23 | 16.1 |
|---|
Completed day 4
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.1 |
|---|
| 1 | 16.2 |
|---|
| 2 | 16.2 |
|---|
| 3 | 16.2 |
|---|
| 4 | 16.2 |
|---|
| 5 | 16.2 |
|---|
| 6 | 16.2 |
|---|
| 7 | 16.2 |
|---|
| 8 | 16.2 |
|---|
| 9 | 16.2 |
|---|
| 10 | 16.2 |
|---|
| 11 | 16.2 |
|---|
| 12 | 16.2 |
|---|
| 13 | 16.2 |
|---|
| 14 | 16.2 |
|---|
| 15 | 16.2 |
|---|
| 16 | 16.2 |
|---|
| 17 | 16.2 |
|---|
| 18 | 16.2 |
|---|
| 19 | 16.2 |
|---|
| 20 | 16.3 |
|---|
| 21 | 16.3 |
|---|
| 22 | 16.3 |
|---|
| 23 | 16.3 |
|---|
Completed day 5
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.3 |
|---|
| 1 | 16.3 |
|---|
| 2 | 16.3 |
|---|
| 3 | 16.3 |
|---|
| 4 | 16.3 |
|---|
| 5 | 16.3 |
|---|
| 6 | 16.3 |
|---|
| 7 | 16.3 |
|---|
| 8 | 16.3 |
|---|
| 9 | 16.3 |
|---|
| 10 | 16.3 |
|---|
| 11 | 16.3 |
|---|
| 12 | 16.3 |
|---|
| 13 | 16.3 |
|---|
| 14 | 16.3 |
|---|
| 15 | 16.4 |
|---|
| 16 | 16.4 |
|---|
| 17 | 16.4 |
|---|
| 18 | 16.4 |
|---|
| 19 | 16.4 |
|---|
| 20 | 16.4 |
|---|
| 21 | 16.4 |
|---|
| 22 | 16.4 |
|---|
| 23 | 16.4 |
|---|
Completed day 6
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.4 |
|---|
| 1 | 16.4 |
|---|
| 2 | 16.4 |
|---|
| 3 | 16.4 |
|---|
| 4 | 16.4 |
|---|
| 5 | 16.4 |
|---|
| 6 | 16.4 |
|---|
| 7 | 16.4 |
|---|
| 8 | 16.4 |
|---|
| 9 | 16.4 |
|---|
| 10 | 16.4 |
|---|
| 11 | 16.5 |
|---|
| 12 | 16.5 |
|---|
| 13 | 16.5 |
|---|
| 14 | 16.5 |
|---|
| 15 | 16.5 |
|---|
| 16 | 16.5 |
|---|
| 17 | 16.5 |
|---|
| 18 | 16.5 |
|---|
| 19 | 16.5 |
|---|
| 20 | 16.5 |
|---|
| 21 | 16.5 |
|---|
| 22 | 16.5 |
|---|
| 23 | 16.5 |
|---|
Completed day 7
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.5 |
|---|
| 1 | 16.5 |
|---|
| 2 | 16.5 |
|---|
| 3 | 16.5 |
|---|
| 4 | 16.5 |
|---|
| 5 | 16.5 |
|---|
| 6 | 16.6 |
|---|
| 7 | 16.6 |
|---|
| 8 | 16.6 |
|---|
| 9 | 16.6 |
|---|
| 10 | 16.6 |
|---|
| 11 | 16.6 |
|---|
| 12 | 16.6 |
|---|
| 13 | 16.6 |
|---|
| 14 | 16.6 |
|---|
| 15 | 16.6 |
|---|
| 16 | 16.6 |
|---|
| 17 | 16.6 |
|---|
| 18 | 16.6 |
|---|
| 19 | 16.6 |
|---|
| 20 | 16.6 |
|---|
| 21 | 16.6 |
|---|
| 22 | 16.6 |
|---|
| 23 | 16.6 |
|---|
Completed day 8
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.6 |
|---|
| 1 | 16.6 |
|---|
| 2 | 16.7 |
|---|
| 3 | 16.7 |
|---|
| 4 | 16.7 |
|---|
| 5 | 16.7 |
|---|
| 6 | 16.7 |
|---|
| 7 | 16.7 |
|---|
| 8 | 16.7 |
|---|
| 9 | 16.7 |
|---|
| 10 | 16.7 |
|---|
| 11 | 16.7 |
|---|
| 12 | 16.7 |
|---|
| 13 | 16.7 |
|---|
| 14 | 16.7 |
|---|
| 15 | 16.7 |
|---|
| 16 | 16.7 |
|---|
| 17 | 16.7 |
|---|
| 18 | 16.7 |
|---|
| 19 | 16.7 |
|---|
| 20 | 16.7 |
|---|
| 21 | 16.8 |
|---|
| 22 | 16.8 |
|---|
| 23 | 16.8 |
|---|
Completed day 9
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.8 |
|---|
| 1 | 16.8 |
|---|
| 2 | 16.8 |
|---|
| 3 | 16.8 |
|---|
| 4 | 16.8 |
|---|
| 5 | 16.8 |
|---|
| 6 | 16.8 |
|---|
| 7 | 16.8 |
|---|
| 8 | 16.8 |
|---|
| 9 | 16.8 |
|---|
| 10 | 16.8 |
|---|
| 11 | 16.8 |
|---|
| 12 | 16.8 |
|---|
| 13 | 16.8 |
|---|
| 14 | 16.8 |
|---|
| 15 | 16.8 |
|---|
| 16 | 16.8 |
|---|
| 17 | 16.9 |
|---|
| 18 | 16.9 |
|---|
| 19 | 16.9 |
|---|
| 20 | 16.9 |
|---|
| 21 | 16.9 |
|---|
| 22 | 16.9 |
|---|
| 23 | 16.9 |
|---|
Completed day 10
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.9 |
|---|
| 1 | 16.9 |
|---|
| 2 | 16.9 |
|---|
| 3 | 16.9 |
|---|
| 4 | 16.9 |
|---|
| 5 | 16.9 |
|---|
| 6 | 16.9 |
|---|
| 7 | 16.9 |
|---|
| 8 | 16.9 |
|---|
| 9 | 16.9 |
|---|
| 10 | 16.9 |
|---|
| 11 | 16.9 |
|---|
| 12 | 17.0 |
|---|
| 13 | 17.0 |
|---|
| 14 | 17.0 |
|---|
| 15 | 17.0 |
|---|
| 16 | 17.0 |
|---|
| 17 | 17.0 |
|---|
| 18 | 17.0 |
|---|
| 19 | 17.0 |
|---|
| 20 | 17.0 |
|---|
| 21 | 17.0 |
|---|
| 22 | 17.0 |
|---|
| 23 | 17.0 |
|---|
Completed day 11
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.0 |
|---|
| 1 | 17.0 |
|---|
| 2 | 17.0 |
|---|
| 3 | 17.0 |
|---|
| 4 | 17.0 |
|---|
| 5 | 17.0 |
|---|
| 6 | 17.0 |
|---|
| 7 | 17.0 |
|---|
| 8 | 17.1 |
|---|
| 9 | 17.1 |
|---|
| 10 | 17.1 |
|---|
| 11 | 17.1 |
|---|
| 12 | 17.1 |
|---|
| 13 | 17.1 |
|---|
| 14 | 17.1 |
|---|
| 15 | 17.1 |
|---|
| 16 | 17.1 |
|---|
| 17 | 17.1 |
|---|
| 18 | 17.1 |
|---|
| 19 | 17.1 |
|---|
| 20 | 17.1 |
|---|
| 21 | 17.1 |
|---|
| 22 | 17.1 |
|---|
| 23 | 17.1 |
|---|
Completed day 12
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.1 |
|---|
| 1 | 17.1 |
|---|
| 2 | 17.1 |
|---|
| 3 | 17.1 |
|---|
| 4 | 17.2 |
|---|
| 5 | 17.2 |
|---|
| 6 | 17.2 |
|---|
| 7 | 17.2 |
|---|
| 8 | 17.2 |
|---|
| 9 | 17.2 |
|---|
| 10 | 17.2 |
|---|
| 11 | 17.2 |
|---|
| 12 | 17.2 |
|---|
| 13 | 17.2 |
|---|
| 14 | 17.2 |
|---|
| 15 | 17.2 |
|---|
| 16 | 17.2 |
|---|
| 17 | 17.2 |
|---|
| 18 | 17.2 |
|---|
| 19 | 17.2 |
|---|
| 20 | 17.2 |
|---|
| 21 | 17.2 |
|---|
| 22 | 17.2 |
|---|
| 23 | 17.3 |
|---|
Completed day 13
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.3 |
|---|
| 1 | 17.3 |
|---|
| 2 | 17.3 |
|---|
| 3 | 17.3 |
|---|
| 4 | 17.3 |
|---|
| 5 | 17.3 |
|---|
| 6 | 17.3 |
|---|
| 7 | 17.3 |
|---|
| 8 | 17.3 |
|---|
| 9 | 17.3 |
|---|
| 10 | 17.3 |
|---|
| 11 | 17.3 |
|---|
| 12 | 17.3 |
|---|
| 13 | 17.3 |
|---|
| 14 | 17.3 |
|---|
| 15 | 17.3 |
|---|
| 16 | 17.3 |
|---|
| 17 | 17.3 |
|---|
| 18 | 17.3 |
|---|
| 19 | 17.4 |
|---|
| 20 | 17.4 |
|---|
| 21 | 17.4 |
|---|
| 22 | 17.4 |
|---|
| 23 | 17.4 |
|---|
Completed day 14
AAP 2022 · Phototherapy · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.4 |
|---|
| 1 | 17.4 |
|---|
| 2 | 17.4 |
|---|
| 3 | 17.4 |
|---|
| 4 | 17.4 |
|---|
| 5 | 17.4 |
|---|
| 6 | 17.4 |
|---|
| 7 | 17.4 |
|---|
| 8 | 17.4 |
|---|
| 9 | 17.4 |
|---|
| 10 | 17.4 |
|---|
| 11 | 17.4 |
|---|
| 12 | 17.4 |
|---|
| 13 | 17.4 |
|---|
| 14 | 17.4 |
|---|
| 15 | 17.4 |
|---|
| 16 | 17.4 |
|---|
| 17 | 17.4 |
|---|
| 18 | 17.4 |
|---|
| 19 | 17.4 |
|---|
| 20 | 17.4 |
|---|
| 21 | 17.4 |
|---|
| 22 | 17.4 |
|---|
| 23 | 17.4 |
|---|
AAP 2022 · Supplemental Table 2, PDF p23 →
Exchange · no additional neurotoxicity risks
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
- The threshold ≥96 h (eg, 4 completed days) after birth is 27 mg/dL.
Completed day 0
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 18.0 |
|---|
| 2 | 18.2 |
|---|
| 3 | 18.4 |
|---|
| 4 | 18.5 |
|---|
| 5 | 18.7 |
|---|
| 6 | 18.8 |
|---|
| 7 | 19.0 |
|---|
| 8 | 19.1 |
|---|
| 9 | 19.3 |
|---|
| 10 | 19.4 |
|---|
| 11 | 19.6 |
|---|
| 12 | 19.7 |
|---|
| 13 | 19.9 |
|---|
| 14 | 20.0 |
|---|
| 15 | 20.1 |
|---|
| 16 | 20.3 |
|---|
| 17 | 20.4 |
|---|
| 18 | 20.6 |
|---|
| 19 | 20.7 |
|---|
| 20 | 20.8 |
|---|
| 21 | 21.0 |
|---|
| 22 | 21.1 |
|---|
| 23 | 21.2 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.4 |
|---|
| 1 | 21.5 |
|---|
| 2 | 21.6 |
|---|
| 3 | 21.7 |
|---|
| 4 | 21.9 |
|---|
| 5 | 22.0 |
|---|
| 6 | 22.1 |
|---|
| 7 | 22.2 |
|---|
| 8 | 22.3 |
|---|
| 9 | 22.4 |
|---|
| 10 | 22.6 |
|---|
| 11 | 22.7 |
|---|
| 12 | 22.8 |
|---|
| 13 | 22.9 |
|---|
| 14 | 23.0 |
|---|
| 15 | 23.1 |
|---|
| 16 | 23.2 |
|---|
| 17 | 23.3 |
|---|
| 18 | 23.4 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.6 |
|---|
| 21 | 23.7 |
|---|
| 22 | 23.8 |
|---|
| 23 | 23.9 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 24.0 |
|---|
| 1 | 24.1 |
|---|
| 2 | 24.2 |
|---|
| 3 | 24.3 |
|---|
| 4 | 24.4 |
|---|
| 5 | 24.5 |
|---|
| 6 | 24.6 |
|---|
| 7 | 24.7 |
|---|
| 8 | 24.7 |
|---|
| 9 | 24.8 |
|---|
| 10 | 24.9 |
|---|
| 11 | 25.0 |
|---|
| 12 | 25.1 |
|---|
| 13 | 25.2 |
|---|
| 14 | 25.2 |
|---|
| 15 | 25.3 |
|---|
| 16 | 25.4 |
|---|
| 17 | 25.5 |
|---|
| 18 | 25.5 |
|---|
| 19 | 25.6 |
|---|
| 20 | 25.7 |
|---|
| 21 | 25.7 |
|---|
| 22 | 25.8 |
|---|
| 23 | 25.9 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.9 |
|---|
| 1 | 26.0 |
|---|
| 2 | 26.0 |
|---|
| 3 | 26.1 |
|---|
| 4 | 26.2 |
|---|
| 5 | 26.2 |
|---|
| 6 | 26.3 |
|---|
| 7 | 26.3 |
|---|
| 8 | 26.4 |
|---|
| 9 | 26.4 |
|---|
| 10 | 26.5 |
|---|
| 11 | 26.5 |
|---|
| 12 | 26.6 |
|---|
| 13 | 26.6 |
|---|
| 14 | 26.7 |
|---|
| 15 | 26.7 |
|---|
| 16 | 26.7 |
|---|
| 17 | 26.8 |
|---|
| 18 | 26.8 |
|---|
| 19 | 26.9 |
|---|
| 20 | 26.9 |
|---|
| 21 | 26.9 |
|---|
| 22 | 27.0 |
|---|
| 23 | 27.0 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 38+ weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 27.0 |
|---|
| 1 | 27.0 |
|---|
| 2 | 27.0 |
|---|
| 3 | 27.0 |
|---|
| 4 | 27.0 |
|---|
| 5 | 27.0 |
|---|
| 6 | 27.0 |
|---|
| 7 | 27.0 |
|---|
| 8 | 27.0 |
|---|
| 9 | 27.0 |
|---|
| 10 | 27.0 |
|---|
| 11 | 27.0 |
|---|
| 12 | 27.0 |
|---|
| 13 | 27.0 |
|---|
| 14 | 27.0 |
|---|
| 15 | 27.0 |
|---|
| 16 | 27.0 |
|---|
| 17 | 27.0 |
|---|
| 18 | 27.0 |
|---|
| 19 | 27.0 |
|---|
| 20 | 27.0 |
|---|
| 21 | 27.0 |
|---|
| 22 | 27.0 |
|---|
| 23 | 27.0 |
|---|
AAP 2022 · Supplemental Table 3, PDF p24 →
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Source footnote inconsistency: Table 3 prints ≥151 h and “6 completed days and 10 h.” Those are not the same age. The published grid is retained without silently correcting the source.
- The threshold ≥151 h (eg, 6 completed days and 10 h) after birth is 27.0 mg/dL.
Completed day 0
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 17.0 |
|---|
| 2 | 17.1 |
|---|
| 3 | 17.3 |
|---|
| 4 | 17.5 |
|---|
| 5 | 17.6 |
|---|
| 6 | 17.8 |
|---|
| 7 | 17.9 |
|---|
| 8 | 18.1 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.4 |
|---|
| 11 | 18.5 |
|---|
| 12 | 18.7 |
|---|
| 13 | 18.8 |
|---|
| 14 | 18.9 |
|---|
| 15 | 19.1 |
|---|
| 16 | 19.2 |
|---|
| 17 | 19.4 |
|---|
| 18 | 19.5 |
|---|
| 19 | 19.6 |
|---|
| 20 | 19.8 |
|---|
| 21 | 19.9 |
|---|
| 22 | 20.1 |
|---|
| 23 | 20.2 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.3 |
|---|
| 1 | 20.5 |
|---|
| 2 | 20.6 |
|---|
| 3 | 20.7 |
|---|
| 4 | 20.8 |
|---|
| 5 | 21.0 |
|---|
| 6 | 21.1 |
|---|
| 7 | 21.2 |
|---|
| 8 | 21.3 |
|---|
| 9 | 21.5 |
|---|
| 10 | 21.6 |
|---|
| 11 | 21.7 |
|---|
| 12 | 21.8 |
|---|
| 13 | 21.9 |
|---|
| 14 | 22.1 |
|---|
| 15 | 22.2 |
|---|
| 16 | 22.3 |
|---|
| 17 | 22.4 |
|---|
| 18 | 22.5 |
|---|
| 19 | 22.6 |
|---|
| 20 | 22.7 |
|---|
| 21 | 22.8 |
|---|
| 22 | 22.9 |
|---|
| 23 | 23.0 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.1 |
|---|
| 1 | 23.2 |
|---|
| 2 | 23.3 |
|---|
| 3 | 23.4 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.6 |
|---|
| 6 | 23.7 |
|---|
| 7 | 23.8 |
|---|
| 8 | 23.9 |
|---|
| 9 | 24.0 |
|---|
| 10 | 24.1 |
|---|
| 11 | 24.2 |
|---|
| 12 | 24.3 |
|---|
| 13 | 24.4 |
|---|
| 14 | 24.5 |
|---|
| 15 | 24.5 |
|---|
| 16 | 24.6 |
|---|
| 17 | 24.7 |
|---|
| 18 | 24.8 |
|---|
| 19 | 24.9 |
|---|
| 20 | 24.9 |
|---|
| 21 | 25.0 |
|---|
| 22 | 25.1 |
|---|
| 23 | 25.2 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.2 |
|---|
| 1 | 25.3 |
|---|
| 2 | 25.4 |
|---|
| 3 | 25.5 |
|---|
| 4 | 25.5 |
|---|
| 5 | 25.6 |
|---|
| 6 | 25.7 |
|---|
| 7 | 25.7 |
|---|
| 8 | 25.8 |
|---|
| 9 | 25.8 |
|---|
| 10 | 25.9 |
|---|
| 11 | 26.0 |
|---|
| 12 | 26.0 |
|---|
| 13 | 26.1 |
|---|
| 14 | 26.1 |
|---|
| 15 | 26.2 |
|---|
| 16 | 26.2 |
|---|
| 17 | 26.3 |
|---|
| 18 | 26.3 |
|---|
| 19 | 26.4 |
|---|
| 20 | 26.4 |
|---|
| 21 | 26.5 |
|---|
| 22 | 26.5 |
|---|
| 23 | 26.5 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.6 |
|---|
| 1 | 26.6 |
|---|
| 2 | 26.6 |
|---|
| 3 | 26.6 |
|---|
| 4 | 26.6 |
|---|
| 5 | 26.6 |
|---|
| 6 | 26.6 |
|---|
| 7 | 26.6 |
|---|
| 8 | 26.6 |
|---|
| 9 | 26.6 |
|---|
| 10 | 26.6 |
|---|
| 11 | 26.7 |
|---|
| 12 | 26.7 |
|---|
| 13 | 26.7 |
|---|
| 14 | 26.7 |
|---|
| 15 | 26.7 |
|---|
| 16 | 26.7 |
|---|
| 17 | 26.7 |
|---|
| 18 | 26.7 |
|---|
| 19 | 26.7 |
|---|
| 20 | 26.7 |
|---|
| 21 | 26.7 |
|---|
| 22 | 26.7 |
|---|
| 23 | 26.7 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.7 |
|---|
| 1 | 26.7 |
|---|
| 2 | 26.8 |
|---|
| 3 | 26.8 |
|---|
| 4 | 26.8 |
|---|
| 5 | 26.8 |
|---|
| 6 | 26.8 |
|---|
| 7 | 26.8 |
|---|
| 8 | 26.8 |
|---|
| 9 | 26.8 |
|---|
| 10 | 26.8 |
|---|
| 11 | 26.8 |
|---|
| 12 | 26.8 |
|---|
| 13 | 26.8 |
|---|
| 14 | 26.8 |
|---|
| 15 | 26.8 |
|---|
| 16 | 26.8 |
|---|
| 17 | 26.8 |
|---|
| 18 | 26.9 |
|---|
| 19 | 26.9 |
|---|
| 20 | 26.9 |
|---|
| 21 | 26.9 |
|---|
| 22 | 26.9 |
|---|
| 23 | 26.9 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 37 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.9 |
|---|
| 1 | 26.9 |
|---|
| 2 | 26.9 |
|---|
| 3 | 26.9 |
|---|
| 4 | 26.9 |
|---|
| 5 | 26.9 |
|---|
| 6 | 26.9 |
|---|
| 7 | 26.9 |
|---|
| 8 | 26.9 |
|---|
| 9 | 26.9 |
|---|
| 10 | 27.0 |
|---|
| 11 | 27.0 |
|---|
| 12 | 27.0 |
|---|
| 13 | 27.0 |
|---|
| 14 | 27.0 |
|---|
| 15 | 27.0 |
|---|
| 16 | 27.0 |
|---|
| 17 | 27.0 |
|---|
| 18 | 27.0 |
|---|
| 19 | 27.0 |
|---|
| 20 | 27.0 |
|---|
| 21 | 27.0 |
|---|
| 22 | 27.0 |
|---|
| 23 | 27.0 |
|---|
AAP 2022 · Supplemental Table 3, PDF p24 →
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 15.9 |
|---|
| 2 | 16.1 |
|---|
| 3 | 16.2 |
|---|
| 4 | 16.4 |
|---|
| 5 | 16.5 |
|---|
| 6 | 16.7 |
|---|
| 7 | 16.8 |
|---|
| 8 | 16.9 |
|---|
| 9 | 17.1 |
|---|
| 10 | 17.2 |
|---|
| 11 | 17.4 |
|---|
| 12 | 17.5 |
|---|
| 13 | 17.7 |
|---|
| 14 | 17.8 |
|---|
| 15 | 17.9 |
|---|
| 16 | 18.1 |
|---|
| 17 | 18.2 |
|---|
| 18 | 18.3 |
|---|
| 19 | 18.5 |
|---|
| 20 | 18.6 |
|---|
| 21 | 18.7 |
|---|
| 22 | 18.9 |
|---|
| 23 | 19.0 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.1 |
|---|
| 1 | 19.2 |
|---|
| 2 | 19.4 |
|---|
| 3 | 19.5 |
|---|
| 4 | 19.6 |
|---|
| 5 | 19.7 |
|---|
| 6 | 19.9 |
|---|
| 7 | 20.0 |
|---|
| 8 | 20.1 |
|---|
| 9 | 20.2 |
|---|
| 10 | 20.4 |
|---|
| 11 | 20.5 |
|---|
| 12 | 20.6 |
|---|
| 13 | 20.7 |
|---|
| 14 | 20.8 |
|---|
| 15 | 20.9 |
|---|
| 16 | 21.0 |
|---|
| 17 | 21.2 |
|---|
| 18 | 21.3 |
|---|
| 19 | 21.4 |
|---|
| 20 | 21.5 |
|---|
| 21 | 21.6 |
|---|
| 22 | 21.7 |
|---|
| 23 | 21.8 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.9 |
|---|
| 1 | 22.0 |
|---|
| 2 | 22.1 |
|---|
| 3 | 22.2 |
|---|
| 4 | 22.3 |
|---|
| 5 | 22.4 |
|---|
| 6 | 22.5 |
|---|
| 7 | 22.6 |
|---|
| 8 | 22.7 |
|---|
| 9 | 22.8 |
|---|
| 10 | 22.9 |
|---|
| 11 | 23.0 |
|---|
| 12 | 23.1 |
|---|
| 13 | 23.2 |
|---|
| 14 | 23.2 |
|---|
| 15 | 23.3 |
|---|
| 16 | 23.4 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.6 |
|---|
| 19 | 23.7 |
|---|
| 20 | 23.8 |
|---|
| 21 | 23.8 |
|---|
| 22 | 23.9 |
|---|
| 23 | 24.0 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 24.1 |
|---|
| 1 | 24.1 |
|---|
| 2 | 24.2 |
|---|
| 3 | 24.3 |
|---|
| 4 | 24.4 |
|---|
| 5 | 24.4 |
|---|
| 6 | 24.5 |
|---|
| 7 | 24.6 |
|---|
| 8 | 24.6 |
|---|
| 9 | 24.7 |
|---|
| 10 | 24.8 |
|---|
| 11 | 24.8 |
|---|
| 12 | 24.9 |
|---|
| 13 | 25.0 |
|---|
| 14 | 25.0 |
|---|
| 15 | 25.1 |
|---|
| 16 | 25.2 |
|---|
| 17 | 25.2 |
|---|
| 18 | 25.3 |
|---|
| 19 | 25.3 |
|---|
| 20 | 25.4 |
|---|
| 21 | 25.4 |
|---|
| 22 | 25.5 |
|---|
| 23 | 25.5 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.5 |
|---|
| 1 | 25.5 |
|---|
| 2 | 25.5 |
|---|
| 3 | 25.6 |
|---|
| 4 | 25.6 |
|---|
| 5 | 25.6 |
|---|
| 6 | 25.6 |
|---|
| 7 | 25.6 |
|---|
| 8 | 25.6 |
|---|
| 9 | 25.6 |
|---|
| 10 | 25.6 |
|---|
| 11 | 25.6 |
|---|
| 12 | 25.6 |
|---|
| 13 | 25.6 |
|---|
| 14 | 25.6 |
|---|
| 15 | 25.7 |
|---|
| 16 | 25.7 |
|---|
| 17 | 25.7 |
|---|
| 18 | 25.7 |
|---|
| 19 | 25.7 |
|---|
| 20 | 25.7 |
|---|
| 21 | 25.7 |
|---|
| 22 | 25.7 |
|---|
| 23 | 25.7 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.7 |
|---|
| 1 | 25.7 |
|---|
| 2 | 25.7 |
|---|
| 3 | 25.7 |
|---|
| 4 | 25.8 |
|---|
| 5 | 25.8 |
|---|
| 6 | 25.8 |
|---|
| 7 | 25.8 |
|---|
| 8 | 25.8 |
|---|
| 9 | 25.8 |
|---|
| 10 | 25.8 |
|---|
| 11 | 25.8 |
|---|
| 12 | 25.8 |
|---|
| 13 | 25.8 |
|---|
| 14 | 25.8 |
|---|
| 15 | 25.8 |
|---|
| 16 | 25.8 |
|---|
| 17 | 25.9 |
|---|
| 18 | 25.9 |
|---|
| 19 | 25.9 |
|---|
| 20 | 25.9 |
|---|
| 21 | 25.9 |
|---|
| 22 | 25.9 |
|---|
| 23 | 25.9 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.9 |
|---|
| 1 | 25.9 |
|---|
| 2 | 25.9 |
|---|
| 3 | 25.9 |
|---|
| 4 | 25.9 |
|---|
| 5 | 25.9 |
|---|
| 6 | 26.0 |
|---|
| 7 | 26.0 |
|---|
| 8 | 26.0 |
|---|
| 9 | 26.0 |
|---|
| 10 | 26.0 |
|---|
| 11 | 26.0 |
|---|
| 12 | 26.0 |
|---|
| 13 | 26.0 |
|---|
| 14 | 26.0 |
|---|
| 15 | 26.0 |
|---|
| 16 | 26.0 |
|---|
| 17 | 26.0 |
|---|
| 18 | 26.0 |
|---|
| 19 | 26.0 |
|---|
| 20 | 26.1 |
|---|
| 21 | 26.1 |
|---|
| 22 | 26.1 |
|---|
| 23 | 26.1 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.1 |
|---|
| 1 | 26.1 |
|---|
| 2 | 26.1 |
|---|
| 3 | 26.1 |
|---|
| 4 | 26.1 |
|---|
| 5 | 26.1 |
|---|
| 6 | 26.1 |
|---|
| 7 | 26.1 |
|---|
| 8 | 26.1 |
|---|
| 9 | 26.1 |
|---|
| 10 | 26.2 |
|---|
| 11 | 26.2 |
|---|
| 12 | 26.2 |
|---|
| 13 | 26.2 |
|---|
| 14 | 26.2 |
|---|
| 15 | 26.2 |
|---|
| 16 | 26.2 |
|---|
| 17 | 26.2 |
|---|
| 18 | 26.2 |
|---|
| 19 | 26.2 |
|---|
| 20 | 26.2 |
|---|
| 21 | 26.2 |
|---|
| 22 | 26.2 |
|---|
| 23 | 26.2 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.2 |
|---|
| 1 | 26.3 |
|---|
| 2 | 26.3 |
|---|
| 3 | 26.3 |
|---|
| 4 | 26.3 |
|---|
| 5 | 26.3 |
|---|
| 6 | 26.3 |
|---|
| 7 | 26.3 |
|---|
| 8 | 26.3 |
|---|
| 9 | 26.3 |
|---|
| 10 | 26.3 |
|---|
| 11 | 26.3 |
|---|
| 12 | 26.3 |
|---|
| 13 | 26.3 |
|---|
| 14 | 26.3 |
|---|
| 15 | 26.3 |
|---|
| 16 | 26.4 |
|---|
| 17 | 26.4 |
|---|
| 18 | 26.4 |
|---|
| 19 | 26.4 |
|---|
| 20 | 26.4 |
|---|
| 21 | 26.4 |
|---|
| 22 | 26.4 |
|---|
| 23 | 26.4 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.4 |
|---|
| 1 | 26.4 |
|---|
| 2 | 26.4 |
|---|
| 3 | 26.4 |
|---|
| 4 | 26.4 |
|---|
| 5 | 26.4 |
|---|
| 6 | 26.4 |
|---|
| 7 | 26.4 |
|---|
| 8 | 26.5 |
|---|
| 9 | 26.5 |
|---|
| 10 | 26.5 |
|---|
| 11 | 26.5 |
|---|
| 12 | 26.5 |
|---|
| 13 | 26.5 |
|---|
| 14 | 26.5 |
|---|
| 15 | 26.5 |
|---|
| 16 | 26.5 |
|---|
| 17 | 26.5 |
|---|
| 18 | 26.5 |
|---|
| 19 | 26.5 |
|---|
| 20 | 26.5 |
|---|
| 21 | 26.5 |
|---|
| 22 | 26.5 |
|---|
| 23 | 26.5 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.5 |
|---|
| 1 | 26.6 |
|---|
| 2 | 26.6 |
|---|
| 3 | 26.6 |
|---|
| 4 | 26.6 |
|---|
| 5 | 26.6 |
|---|
| 6 | 26.6 |
|---|
| 7 | 26.6 |
|---|
| 8 | 26.6 |
|---|
| 9 | 26.6 |
|---|
| 10 | 26.6 |
|---|
| 11 | 26.6 |
|---|
| 12 | 26.6 |
|---|
| 13 | 26.6 |
|---|
| 14 | 26.6 |
|---|
| 15 | 26.6 |
|---|
| 16 | 26.6 |
|---|
| 17 | 26.6 |
|---|
| 18 | 26.7 |
|---|
| 19 | 26.7 |
|---|
| 20 | 26.7 |
|---|
| 21 | 26.7 |
|---|
| 22 | 26.7 |
|---|
| 23 | 26.7 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.7 |
|---|
| 1 | 26.7 |
|---|
| 2 | 26.7 |
|---|
| 3 | 26.7 |
|---|
| 4 | 26.7 |
|---|
| 5 | 26.7 |
|---|
| 6 | 26.7 |
|---|
| 7 | 26.7 |
|---|
| 8 | 26.7 |
|---|
| 9 | 26.7 |
|---|
| 10 | 26.7 |
|---|
| 11 | 26.7 |
|---|
| 12 | 26.7 |
|---|
| 13 | 26.8 |
|---|
| 14 | 26.8 |
|---|
| 15 | 26.8 |
|---|
| 16 | 26.8 |
|---|
| 17 | 26.8 |
|---|
| 18 | 26.8 |
|---|
| 19 | 26.8 |
|---|
| 20 | 26.8 |
|---|
| 21 | 26.8 |
|---|
| 22 | 26.8 |
|---|
| 23 | 26.8 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.8 |
|---|
| 1 | 26.8 |
|---|
| 2 | 26.8 |
|---|
| 3 | 26.8 |
|---|
| 4 | 26.8 |
|---|
| 5 | 26.8 |
|---|
| 6 | 26.8 |
|---|
| 7 | 26.8 |
|---|
| 8 | 26.8 |
|---|
| 9 | 26.9 |
|---|
| 10 | 26.9 |
|---|
| 11 | 26.9 |
|---|
| 12 | 26.9 |
|---|
| 13 | 26.9 |
|---|
| 14 | 26.9 |
|---|
| 15 | 26.9 |
|---|
| 16 | 26.9 |
|---|
| 17 | 26.9 |
|---|
| 18 | 26.9 |
|---|
| 19 | 26.9 |
|---|
| 20 | 26.9 |
|---|
| 21 | 26.9 |
|---|
| 22 | 26.9 |
|---|
| 23 | 26.9 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.9 |
|---|
| 1 | 26.9 |
|---|
| 2 | 26.9 |
|---|
| 3 | 26.9 |
|---|
| 4 | 26.9 |
|---|
| 5 | 26.9 |
|---|
| 6 | 27.0 |
|---|
| 7 | 27.0 |
|---|
| 8 | 27.0 |
|---|
| 9 | 27.0 |
|---|
| 10 | 27.0 |
|---|
| 11 | 27.0 |
|---|
| 12 | 27.0 |
|---|
| 13 | 27.0 |
|---|
| 14 | 27.0 |
|---|
| 15 | 27.0 |
|---|
| 16 | 27.0 |
|---|
| 17 | 27.0 |
|---|
| 18 | 27.0 |
|---|
| 19 | 27.0 |
|---|
| 20 | 27.0 |
|---|
| 21 | 27.0 |
|---|
| 22 | 27.0 |
|---|
| 23 | 27.0 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 36 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 27.0 |
|---|
| 1 | 27.0 |
|---|
| 2 | 27.0 |
|---|
| 3 | 27.0 |
|---|
| 4 | 27.0 |
|---|
| 5 | 27.0 |
|---|
| 6 | 27.0 |
|---|
| 7 | 27.0 |
|---|
| 8 | 27.0 |
|---|
| 9 | 27.0 |
|---|
| 10 | 27.0 |
|---|
| 11 | 27.0 |
|---|
| 12 | 27.0 |
|---|
| 13 | 27.0 |
|---|
| 14 | 27.0 |
|---|
| 15 | 27.0 |
|---|
| 16 | 27.0 |
|---|
| 17 | 27.0 |
|---|
| 18 | 27.0 |
|---|
| 19 | 27.0 |
|---|
| 20 | 27.0 |
|---|
| 21 | 27.0 |
|---|
| 22 | 27.0 |
|---|
| 23 | 27.0 |
|---|
AAP 2022 · Supplemental Table 3, PDF p24 →
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL
Use the GA-specific table only when there are no additional neurotoxicity risks.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 14.9 |
|---|
| 2 | 15.0 |
|---|
| 3 | 15.1 |
|---|
| 4 | 15.3 |
|---|
| 5 | 15.4 |
|---|
| 6 | 15.6 |
|---|
| 7 | 15.7 |
|---|
| 8 | 15.8 |
|---|
| 9 | 16.0 |
|---|
| 10 | 16.1 |
|---|
| 11 | 16.2 |
|---|
| 12 | 16.4 |
|---|
| 13 | 16.5 |
|---|
| 14 | 16.6 |
|---|
| 15 | 16.8 |
|---|
| 16 | 16.9 |
|---|
| 17 | 17.0 |
|---|
| 18 | 17.2 |
|---|
| 19 | 17.3 |
|---|
| 20 | 17.4 |
|---|
| 21 | 17.5 |
|---|
| 22 | 17.7 |
|---|
| 23 | 17.8 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.9 |
|---|
| 1 | 18.0 |
|---|
| 2 | 18.2 |
|---|
| 3 | 18.3 |
|---|
| 4 | 18.4 |
|---|
| 5 | 18.5 |
|---|
| 6 | 18.7 |
|---|
| 7 | 18.8 |
|---|
| 8 | 18.9 |
|---|
| 9 | 19.0 |
|---|
| 10 | 19.1 |
|---|
| 11 | 19.2 |
|---|
| 12 | 19.4 |
|---|
| 13 | 19.5 |
|---|
| 14 | 19.6 |
|---|
| 15 | 19.7 |
|---|
| 16 | 19.8 |
|---|
| 17 | 19.9 |
|---|
| 18 | 20.0 |
|---|
| 19 | 20.1 |
|---|
| 20 | 20.2 |
|---|
| 21 | 20.3 |
|---|
| 22 | 20.5 |
|---|
| 23 | 20.6 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.7 |
|---|
| 1 | 20.8 |
|---|
| 2 | 20.9 |
|---|
| 3 | 21.0 |
|---|
| 4 | 21.1 |
|---|
| 5 | 21.2 |
|---|
| 6 | 21.3 |
|---|
| 7 | 21.4 |
|---|
| 8 | 21.5 |
|---|
| 9 | 21.6 |
|---|
| 10 | 21.7 |
|---|
| 11 | 21.7 |
|---|
| 12 | 21.8 |
|---|
| 13 | 21.9 |
|---|
| 14 | 22.0 |
|---|
| 15 | 22.1 |
|---|
| 16 | 22.2 |
|---|
| 17 | 22.3 |
|---|
| 18 | 22.4 |
|---|
| 19 | 22.5 |
|---|
| 20 | 22.6 |
|---|
| 21 | 22.6 |
|---|
| 22 | 22.7 |
|---|
| 23 | 22.8 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.9 |
|---|
| 1 | 23.0 |
|---|
| 2 | 23.1 |
|---|
| 3 | 23.1 |
|---|
| 4 | 23.2 |
|---|
| 5 | 23.3 |
|---|
| 6 | 23.4 |
|---|
| 7 | 23.4 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.6 |
|---|
| 10 | 23.7 |
|---|
| 11 | 23.7 |
|---|
| 12 | 23.8 |
|---|
| 13 | 23.9 |
|---|
| 14 | 23.9 |
|---|
| 15 | 24.0 |
|---|
| 16 | 24.1 |
|---|
| 17 | 24.1 |
|---|
| 18 | 24.2 |
|---|
| 19 | 24.3 |
|---|
| 20 | 24.3 |
|---|
| 21 | 24.4 |
|---|
| 22 | 24.4 |
|---|
| 23 | 24.5 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 24.5 |
|---|
| 1 | 24.5 |
|---|
| 2 | 24.5 |
|---|
| 3 | 24.5 |
|---|
| 4 | 24.5 |
|---|
| 5 | 24.5 |
|---|
| 6 | 24.5 |
|---|
| 7 | 24.5 |
|---|
| 8 | 24.6 |
|---|
| 9 | 24.6 |
|---|
| 10 | 24.6 |
|---|
| 11 | 24.6 |
|---|
| 12 | 24.6 |
|---|
| 13 | 24.6 |
|---|
| 14 | 24.6 |
|---|
| 15 | 24.6 |
|---|
| 16 | 24.6 |
|---|
| 17 | 24.6 |
|---|
| 18 | 24.6 |
|---|
| 19 | 24.7 |
|---|
| 20 | 24.7 |
|---|
| 21 | 24.7 |
|---|
| 22 | 24.7 |
|---|
| 23 | 24.7 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 24.7 |
|---|
| 1 | 24.7 |
|---|
| 2 | 24.7 |
|---|
| 3 | 24.7 |
|---|
| 4 | 24.7 |
|---|
| 5 | 24.8 |
|---|
| 6 | 24.8 |
|---|
| 7 | 24.8 |
|---|
| 8 | 24.8 |
|---|
| 9 | 24.8 |
|---|
| 10 | 24.8 |
|---|
| 11 | 24.8 |
|---|
| 12 | 24.8 |
|---|
| 13 | 24.8 |
|---|
| 14 | 24.8 |
|---|
| 15 | 24.8 |
|---|
| 16 | 24.9 |
|---|
| 17 | 24.9 |
|---|
| 18 | 24.9 |
|---|
| 19 | 24.9 |
|---|
| 20 | 24.9 |
|---|
| 21 | 24.9 |
|---|
| 22 | 24.9 |
|---|
| 23 | 24.9 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 24.9 |
|---|
| 1 | 24.9 |
|---|
| 2 | 24.9 |
|---|
| 3 | 25.0 |
|---|
| 4 | 25.0 |
|---|
| 5 | 25.0 |
|---|
| 6 | 25.0 |
|---|
| 7 | 25.0 |
|---|
| 8 | 25.0 |
|---|
| 9 | 25.0 |
|---|
| 10 | 25.0 |
|---|
| 11 | 25.0 |
|---|
| 12 | 25.0 |
|---|
| 13 | 25.0 |
|---|
| 14 | 25.0 |
|---|
| 15 | 25.1 |
|---|
| 16 | 25.1 |
|---|
| 17 | 25.1 |
|---|
| 18 | 25.1 |
|---|
| 19 | 25.1 |
|---|
| 20 | 25.1 |
|---|
| 21 | 25.1 |
|---|
| 22 | 25.1 |
|---|
| 23 | 25.1 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.1 |
|---|
| 1 | 25.1 |
|---|
| 2 | 25.2 |
|---|
| 3 | 25.2 |
|---|
| 4 | 25.2 |
|---|
| 5 | 25.2 |
|---|
| 6 | 25.2 |
|---|
| 7 | 25.2 |
|---|
| 8 | 25.2 |
|---|
| 9 | 25.2 |
|---|
| 10 | 25.2 |
|---|
| 11 | 25.2 |
|---|
| 12 | 25.2 |
|---|
| 13 | 25.2 |
|---|
| 14 | 25.3 |
|---|
| 15 | 25.3 |
|---|
| 16 | 25.3 |
|---|
| 17 | 25.3 |
|---|
| 18 | 25.3 |
|---|
| 19 | 25.3 |
|---|
| 20 | 25.3 |
|---|
| 21 | 25.3 |
|---|
| 22 | 25.3 |
|---|
| 23 | 25.3 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.3 |
|---|
| 1 | 25.3 |
|---|
| 2 | 25.3 |
|---|
| 3 | 25.4 |
|---|
| 4 | 25.4 |
|---|
| 5 | 25.4 |
|---|
| 6 | 25.4 |
|---|
| 7 | 25.4 |
|---|
| 8 | 25.4 |
|---|
| 9 | 25.4 |
|---|
| 10 | 25.4 |
|---|
| 11 | 25.4 |
|---|
| 12 | 25.4 |
|---|
| 13 | 25.4 |
|---|
| 14 | 25.4 |
|---|
| 15 | 25.5 |
|---|
| 16 | 25.5 |
|---|
| 17 | 25.5 |
|---|
| 18 | 25.5 |
|---|
| 19 | 25.5 |
|---|
| 20 | 25.5 |
|---|
| 21 | 25.5 |
|---|
| 22 | 25.5 |
|---|
| 23 | 25.5 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.5 |
|---|
| 1 | 25.5 |
|---|
| 2 | 25.5 |
|---|
| 3 | 25.5 |
|---|
| 4 | 25.6 |
|---|
| 5 | 25.6 |
|---|
| 6 | 25.6 |
|---|
| 7 | 25.6 |
|---|
| 8 | 25.6 |
|---|
| 9 | 25.6 |
|---|
| 10 | 25.6 |
|---|
| 11 | 25.6 |
|---|
| 12 | 25.6 |
|---|
| 13 | 25.6 |
|---|
| 14 | 25.6 |
|---|
| 15 | 25.6 |
|---|
| 16 | 25.6 |
|---|
| 17 | 25.7 |
|---|
| 18 | 25.7 |
|---|
| 19 | 25.7 |
|---|
| 20 | 25.7 |
|---|
| 21 | 25.7 |
|---|
| 22 | 25.7 |
|---|
| 23 | 25.7 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.7 |
|---|
| 1 | 25.7 |
|---|
| 2 | 25.7 |
|---|
| 3 | 25.7 |
|---|
| 4 | 25.7 |
|---|
| 5 | 25.7 |
|---|
| 6 | 25.7 |
|---|
| 7 | 25.8 |
|---|
| 8 | 25.8 |
|---|
| 9 | 25.8 |
|---|
| 10 | 25.8 |
|---|
| 11 | 25.8 |
|---|
| 12 | 25.8 |
|---|
| 13 | 25.8 |
|---|
| 14 | 25.8 |
|---|
| 15 | 25.8 |
|---|
| 16 | 25.8 |
|---|
| 17 | 25.8 |
|---|
| 18 | 25.8 |
|---|
| 19 | 25.8 |
|---|
| 20 | 25.8 |
|---|
| 21 | 25.9 |
|---|
| 22 | 25.9 |
|---|
| 23 | 25.9 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 25.9 |
|---|
| 1 | 25.9 |
|---|
| 2 | 25.9 |
|---|
| 3 | 25.9 |
|---|
| 4 | 25.9 |
|---|
| 5 | 25.9 |
|---|
| 6 | 25.9 |
|---|
| 7 | 25.9 |
|---|
| 8 | 25.9 |
|---|
| 9 | 25.9 |
|---|
| 10 | 25.9 |
|---|
| 11 | 25.9 |
|---|
| 12 | 26.0 |
|---|
| 13 | 26.0 |
|---|
| 14 | 26.0 |
|---|
| 15 | 26.0 |
|---|
| 16 | 26.0 |
|---|
| 17 | 26.0 |
|---|
| 18 | 26.0 |
|---|
| 19 | 26.0 |
|---|
| 20 | 26.0 |
|---|
| 21 | 26.0 |
|---|
| 22 | 26.0 |
|---|
| 23 | 26.0 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.0 |
|---|
| 1 | 26.0 |
|---|
| 2 | 26.0 |
|---|
| 3 | 26.1 |
|---|
| 4 | 26.1 |
|---|
| 5 | 26.1 |
|---|
| 6 | 26.1 |
|---|
| 7 | 26.1 |
|---|
| 8 | 26.1 |
|---|
| 9 | 26.1 |
|---|
| 10 | 26.1 |
|---|
| 11 | 26.1 |
|---|
| 12 | 26.1 |
|---|
| 13 | 26.1 |
|---|
| 14 | 26.1 |
|---|
| 15 | 26.1 |
|---|
| 16 | 26.1 |
|---|
| 17 | 26.1 |
|---|
| 18 | 26.1 |
|---|
| 19 | 26.2 |
|---|
| 20 | 26.2 |
|---|
| 21 | 26.2 |
|---|
| 22 | 26.2 |
|---|
| 23 | 26.2 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.2 |
|---|
| 1 | 26.2 |
|---|
| 2 | 26.2 |
|---|
| 3 | 26.2 |
|---|
| 4 | 26.2 |
|---|
| 5 | 26.2 |
|---|
| 6 | 26.2 |
|---|
| 7 | 26.2 |
|---|
| 8 | 26.2 |
|---|
| 9 | 26.2 |
|---|
| 10 | 26.2 |
|---|
| 11 | 26.2 |
|---|
| 12 | 26.3 |
|---|
| 13 | 26.3 |
|---|
| 14 | 26.3 |
|---|
| 15 | 26.3 |
|---|
| 16 | 26.3 |
|---|
| 17 | 26.3 |
|---|
| 18 | 26.3 |
|---|
| 19 | 26.3 |
|---|
| 20 | 26.3 |
|---|
| 21 | 26.3 |
|---|
| 22 | 26.3 |
|---|
| 23 | 26.3 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 35 weeks · No additional neurotoxicity risk factors · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 26.3 |
|---|
| 1 | 26.3 |
|---|
| 2 | 26.3 |
|---|
| 3 | 26.3 |
|---|
| 4 | 26.3 |
|---|
| 5 | 26.3 |
|---|
| 6 | 26.3 |
|---|
| 7 | 26.3 |
|---|
| 8 | 26.3 |
|---|
| 9 | 26.3 |
|---|
| 10 | 26.3 |
|---|
| 11 | 26.3 |
|---|
| 12 | 26.3 |
|---|
| 13 | 26.3 |
|---|
| 14 | 26.3 |
|---|
| 15 | 26.3 |
|---|
| 16 | 26.3 |
|---|
| 17 | 26.3 |
|---|
| 18 | 26.3 |
|---|
| 19 | 26.3 |
|---|
| 20 | 26.3 |
|---|
| 21 | 26.3 |
|---|
| 22 | 26.3 |
|---|
| 23 | 26.3 |
|---|
AAP 2022 · Supplemental Table 3, PDF p25 →
Exchange · additional neurotoxicity risk(s)
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 14.8 |
|---|
| 2 | 15.0 |
|---|
| 3 | 15.1 |
|---|
| 4 | 15.2 |
|---|
| 5 | 15.4 |
|---|
| 6 | 15.5 |
|---|
| 7 | 15.6 |
|---|
| 8 | 15.8 |
|---|
| 9 | 15.9 |
|---|
| 10 | 16.0 |
|---|
| 11 | 16.1 |
|---|
| 12 | 16.3 |
|---|
| 13 | 16.4 |
|---|
| 14 | 16.5 |
|---|
| 15 | 16.6 |
|---|
| 16 | 16.7 |
|---|
| 17 | 16.9 |
|---|
| 18 | 17.0 |
|---|
| 19 | 17.1 |
|---|
| 20 | 17.2 |
|---|
| 21 | 17.3 |
|---|
| 22 | 17.4 |
|---|
| 23 | 17.6 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.7 |
|---|
| 1 | 17.8 |
|---|
| 2 | 17.9 |
|---|
| 3 | 18.0 |
|---|
| 4 | 18.1 |
|---|
| 5 | 18.2 |
|---|
| 6 | 18.3 |
|---|
| 7 | 18.4 |
|---|
| 8 | 18.5 |
|---|
| 9 | 18.7 |
|---|
| 10 | 18.8 |
|---|
| 11 | 18.9 |
|---|
| 12 | 19.0 |
|---|
| 13 | 19.1 |
|---|
| 14 | 19.2 |
|---|
| 15 | 19.3 |
|---|
| 16 | 19.4 |
|---|
| 17 | 19.5 |
|---|
| 18 | 19.6 |
|---|
| 19 | 19.7 |
|---|
| 20 | 19.8 |
|---|
| 21 | 19.9 |
|---|
| 22 | 19.9 |
|---|
| 23 | 20.0 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.1 |
|---|
| 1 | 20.2 |
|---|
| 2 | 20.3 |
|---|
| 3 | 20.4 |
|---|
| 4 | 20.5 |
|---|
| 5 | 20.6 |
|---|
| 6 | 20.7 |
|---|
| 7 | 20.8 |
|---|
| 8 | 20.8 |
|---|
| 9 | 20.9 |
|---|
| 10 | 21.0 |
|---|
| 11 | 21.1 |
|---|
| 12 | 21.2 |
|---|
| 13 | 21.3 |
|---|
| 14 | 21.3 |
|---|
| 15 | 21.4 |
|---|
| 16 | 21.5 |
|---|
| 17 | 21.6 |
|---|
| 18 | 21.7 |
|---|
| 19 | 21.7 |
|---|
| 20 | 21.8 |
|---|
| 21 | 21.9 |
|---|
| 22 | 22.0 |
|---|
| 23 | 22.0 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.1 |
|---|
| 1 | 22.2 |
|---|
| 2 | 22.2 |
|---|
| 3 | 22.3 |
|---|
| 4 | 22.4 |
|---|
| 5 | 22.5 |
|---|
| 6 | 22.5 |
|---|
| 7 | 22.6 |
|---|
| 8 | 22.7 |
|---|
| 9 | 22.7 |
|---|
| 10 | 22.8 |
|---|
| 11 | 22.8 |
|---|
| 12 | 22.9 |
|---|
| 13 | 23.0 |
|---|
| 14 | 23.0 |
|---|
| 15 | 23.1 |
|---|
| 16 | 23.1 |
|---|
| 17 | 23.2 |
|---|
| 18 | 23.3 |
|---|
| 19 | 23.3 |
|---|
| 20 | 23.4 |
|---|
| 21 | 23.4 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 38+ weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
AAP 2022 · Supplemental Table 4, PDF p25 →
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 14.3 |
|---|
| 2 | 14.4 |
|---|
| 3 | 14.6 |
|---|
| 4 | 14.7 |
|---|
| 5 | 14.8 |
|---|
| 6 | 15.0 |
|---|
| 7 | 15.1 |
|---|
| 8 | 15.2 |
|---|
| 9 | 15.4 |
|---|
| 10 | 15.5 |
|---|
| 11 | 15.6 |
|---|
| 12 | 15.7 |
|---|
| 13 | 15.9 |
|---|
| 14 | 16.0 |
|---|
| 15 | 16.1 |
|---|
| 16 | 16.2 |
|---|
| 17 | 16.4 |
|---|
| 18 | 16.5 |
|---|
| 19 | 16.6 |
|---|
| 20 | 16.7 |
|---|
| 21 | 16.8 |
|---|
| 22 | 17.0 |
|---|
| 23 | 17.1 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 17.2 |
|---|
| 1 | 17.3 |
|---|
| 2 | 17.4 |
|---|
| 3 | 17.5 |
|---|
| 4 | 17.7 |
|---|
| 5 | 17.8 |
|---|
| 6 | 17.9 |
|---|
| 7 | 18.0 |
|---|
| 8 | 18.1 |
|---|
| 9 | 18.2 |
|---|
| 10 | 18.3 |
|---|
| 11 | 18.4 |
|---|
| 12 | 18.5 |
|---|
| 13 | 18.6 |
|---|
| 14 | 18.7 |
|---|
| 15 | 18.8 |
|---|
| 16 | 18.9 |
|---|
| 17 | 19.0 |
|---|
| 18 | 19.1 |
|---|
| 19 | 19.2 |
|---|
| 20 | 19.3 |
|---|
| 21 | 19.4 |
|---|
| 22 | 19.5 |
|---|
| 23 | 19.6 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.7 |
|---|
| 1 | 19.8 |
|---|
| 2 | 19.9 |
|---|
| 3 | 20.0 |
|---|
| 4 | 20.1 |
|---|
| 5 | 20.1 |
|---|
| 6 | 20.2 |
|---|
| 7 | 20.3 |
|---|
| 8 | 20.4 |
|---|
| 9 | 20.5 |
|---|
| 10 | 20.6 |
|---|
| 11 | 20.7 |
|---|
| 12 | 20.7 |
|---|
| 13 | 20.8 |
|---|
| 14 | 20.9 |
|---|
| 15 | 21.0 |
|---|
| 16 | 21.1 |
|---|
| 17 | 21.1 |
|---|
| 18 | 21.2 |
|---|
| 19 | 21.3 |
|---|
| 20 | 21.4 |
|---|
| 21 | 21.4 |
|---|
| 22 | 21.5 |
|---|
| 23 | 21.6 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.7 |
|---|
| 1 | 21.7 |
|---|
| 2 | 21.8 |
|---|
| 3 | 21.9 |
|---|
| 4 | 21.9 |
|---|
| 5 | 22.0 |
|---|
| 6 | 22.1 |
|---|
| 7 | 22.1 |
|---|
| 8 | 22.2 |
|---|
| 9 | 22.3 |
|---|
| 10 | 22.3 |
|---|
| 11 | 22.4 |
|---|
| 12 | 22.5 |
|---|
| 13 | 22.5 |
|---|
| 14 | 22.6 |
|---|
| 15 | 22.6 |
|---|
| 16 | 22.7 |
|---|
| 17 | 22.8 |
|---|
| 18 | 22.8 |
|---|
| 19 | 22.9 |
|---|
| 20 | 22.9 |
|---|
| 21 | 23.0 |
|---|
| 22 | 23.0 |
|---|
| 23 | 23.1 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.1 |
|---|
| 1 | 23.1 |
|---|
| 2 | 23.1 |
|---|
| 3 | 23.1 |
|---|
| 4 | 23.1 |
|---|
| 5 | 23.1 |
|---|
| 6 | 23.1 |
|---|
| 7 | 23.1 |
|---|
| 8 | 23.1 |
|---|
| 9 | 23.1 |
|---|
| 10 | 23.1 |
|---|
| 11 | 23.1 |
|---|
| 12 | 23.2 |
|---|
| 13 | 23.2 |
|---|
| 14 | 23.2 |
|---|
| 15 | 23.2 |
|---|
| 16 | 23.2 |
|---|
| 17 | 23.2 |
|---|
| 18 | 23.2 |
|---|
| 19 | 23.2 |
|---|
| 20 | 23.2 |
|---|
| 21 | 23.2 |
|---|
| 22 | 23.2 |
|---|
| 23 | 23.2 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.2 |
|---|
| 1 | 23.2 |
|---|
| 2 | 23.2 |
|---|
| 3 | 23.2 |
|---|
| 4 | 23.3 |
|---|
| 5 | 23.3 |
|---|
| 6 | 23.3 |
|---|
| 7 | 23.3 |
|---|
| 8 | 23.3 |
|---|
| 9 | 23.3 |
|---|
| 10 | 23.3 |
|---|
| 11 | 23.3 |
|---|
| 12 | 23.3 |
|---|
| 13 | 23.3 |
|---|
| 14 | 23.3 |
|---|
| 15 | 23.3 |
|---|
| 16 | 23.3 |
|---|
| 17 | 23.3 |
|---|
| 18 | 23.3 |
|---|
| 19 | 23.3 |
|---|
| 20 | 23.3 |
|---|
| 21 | 23.4 |
|---|
| 22 | 23.4 |
|---|
| 23 | 23.4 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.4 |
|---|
| 1 | 23.4 |
|---|
| 2 | 23.4 |
|---|
| 3 | 23.4 |
|---|
| 4 | 23.4 |
|---|
| 5 | 23.4 |
|---|
| 6 | 23.4 |
|---|
| 7 | 23.4 |
|---|
| 8 | 23.4 |
|---|
| 9 | 23.4 |
|---|
| 10 | 23.4 |
|---|
| 11 | 23.4 |
|---|
| 12 | 23.4 |
|---|
| 13 | 23.4 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 37 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
AAP 2022 · Supplemental Table 4, PDF p26 →
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 13.7 |
|---|
| 2 | 13.9 |
|---|
| 3 | 14.0 |
|---|
| 4 | 14.1 |
|---|
| 5 | 14.3 |
|---|
| 6 | 14.4 |
|---|
| 7 | 14.5 |
|---|
| 8 | 14.7 |
|---|
| 9 | 14.8 |
|---|
| 10 | 14.9 |
|---|
| 11 | 15.1 |
|---|
| 12 | 15.2 |
|---|
| 13 | 15.3 |
|---|
| 14 | 15.4 |
|---|
| 15 | 15.6 |
|---|
| 16 | 15.7 |
|---|
| 17 | 15.8 |
|---|
| 18 | 15.9 |
|---|
| 19 | 16.1 |
|---|
| 20 | 16.2 |
|---|
| 21 | 16.3 |
|---|
| 22 | 16.4 |
|---|
| 23 | 16.5 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.6 |
|---|
| 1 | 16.8 |
|---|
| 2 | 16.9 |
|---|
| 3 | 17.0 |
|---|
| 4 | 17.1 |
|---|
| 5 | 17.2 |
|---|
| 6 | 17.3 |
|---|
| 7 | 17.4 |
|---|
| 8 | 17.5 |
|---|
| 9 | 17.6 |
|---|
| 10 | 17.7 |
|---|
| 11 | 17.8 |
|---|
| 12 | 17.9 |
|---|
| 13 | 18.0 |
|---|
| 14 | 18.1 |
|---|
| 15 | 18.2 |
|---|
| 16 | 18.3 |
|---|
| 17 | 18.4 |
|---|
| 18 | 18.5 |
|---|
| 19 | 18.6 |
|---|
| 20 | 18.7 |
|---|
| 21 | 18.8 |
|---|
| 22 | 18.9 |
|---|
| 23 | 19.0 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 19.1 |
|---|
| 1 | 19.2 |
|---|
| 2 | 19.2 |
|---|
| 3 | 19.3 |
|---|
| 4 | 19.4 |
|---|
| 5 | 19.5 |
|---|
| 6 | 19.6 |
|---|
| 7 | 19.7 |
|---|
| 8 | 19.7 |
|---|
| 9 | 19.8 |
|---|
| 10 | 19.9 |
|---|
| 11 | 20.0 |
|---|
| 12 | 20.1 |
|---|
| 13 | 20.1 |
|---|
| 14 | 20.2 |
|---|
| 15 | 20.3 |
|---|
| 16 | 20.3 |
|---|
| 17 | 20.4 |
|---|
| 18 | 20.5 |
|---|
| 19 | 20.6 |
|---|
| 20 | 20.6 |
|---|
| 21 | 20.7 |
|---|
| 22 | 20.8 |
|---|
| 23 | 20.8 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.9 |
|---|
| 1 | 20.9 |
|---|
| 2 | 21.0 |
|---|
| 3 | 21.1 |
|---|
| 4 | 21.1 |
|---|
| 5 | 21.2 |
|---|
| 6 | 21.2 |
|---|
| 7 | 21.3 |
|---|
| 8 | 21.4 |
|---|
| 9 | 21.4 |
|---|
| 10 | 21.5 |
|---|
| 11 | 21.5 |
|---|
| 12 | 21.6 |
|---|
| 13 | 21.6 |
|---|
| 14 | 21.7 |
|---|
| 15 | 21.7 |
|---|
| 16 | 21.8 |
|---|
| 17 | 21.8 |
|---|
| 18 | 21.9 |
|---|
| 19 | 21.9 |
|---|
| 20 | 22.0 |
|---|
| 21 | 22.0 |
|---|
| 22 | 22.0 |
|---|
| 23 | 22.1 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.1 |
|---|
| 1 | 22.1 |
|---|
| 2 | 22.1 |
|---|
| 3 | 22.1 |
|---|
| 4 | 22.1 |
|---|
| 5 | 22.1 |
|---|
| 6 | 22.1 |
|---|
| 7 | 22.1 |
|---|
| 8 | 22.1 |
|---|
| 9 | 22.1 |
|---|
| 10 | 22.2 |
|---|
| 11 | 22.2 |
|---|
| 12 | 22.2 |
|---|
| 13 | 22.2 |
|---|
| 14 | 22.2 |
|---|
| 15 | 22.2 |
|---|
| 16 | 22.2 |
|---|
| 17 | 22.2 |
|---|
| 18 | 22.2 |
|---|
| 19 | 22.2 |
|---|
| 20 | 22.2 |
|---|
| 21 | 22.2 |
|---|
| 22 | 22.3 |
|---|
| 23 | 22.3 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.3 |
|---|
| 1 | 22.3 |
|---|
| 2 | 22.3 |
|---|
| 3 | 22.3 |
|---|
| 4 | 22.3 |
|---|
| 5 | 22.3 |
|---|
| 6 | 22.3 |
|---|
| 7 | 22.3 |
|---|
| 8 | 22.3 |
|---|
| 9 | 22.3 |
|---|
| 10 | 22.3 |
|---|
| 11 | 22.4 |
|---|
| 12 | 22.4 |
|---|
| 13 | 22.4 |
|---|
| 14 | 22.4 |
|---|
| 15 | 22.4 |
|---|
| 16 | 22.4 |
|---|
| 17 | 22.4 |
|---|
| 18 | 22.4 |
|---|
| 19 | 22.4 |
|---|
| 20 | 22.4 |
|---|
| 21 | 22.4 |
|---|
| 22 | 22.4 |
|---|
| 23 | 22.4 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.5 |
|---|
| 1 | 22.5 |
|---|
| 2 | 22.5 |
|---|
| 3 | 22.5 |
|---|
| 4 | 22.5 |
|---|
| 5 | 22.5 |
|---|
| 6 | 22.5 |
|---|
| 7 | 22.5 |
|---|
| 8 | 22.5 |
|---|
| 9 | 22.5 |
|---|
| 10 | 22.5 |
|---|
| 11 | 22.5 |
|---|
| 12 | 22.5 |
|---|
| 13 | 22.5 |
|---|
| 14 | 22.6 |
|---|
| 15 | 22.6 |
|---|
| 16 | 22.6 |
|---|
| 17 | 22.6 |
|---|
| 18 | 22.6 |
|---|
| 19 | 22.6 |
|---|
| 20 | 22.6 |
|---|
| 21 | 22.6 |
|---|
| 22 | 22.6 |
|---|
| 23 | 22.6 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.6 |
|---|
| 1 | 22.6 |
|---|
| 2 | 22.6 |
|---|
| 3 | 22.6 |
|---|
| 4 | 22.7 |
|---|
| 5 | 22.7 |
|---|
| 6 | 22.7 |
|---|
| 7 | 22.7 |
|---|
| 8 | 22.7 |
|---|
| 9 | 22.7 |
|---|
| 10 | 22.7 |
|---|
| 11 | 22.7 |
|---|
| 12 | 22.7 |
|---|
| 13 | 22.7 |
|---|
| 14 | 22.7 |
|---|
| 15 | 22.7 |
|---|
| 16 | 22.7 |
|---|
| 17 | 22.7 |
|---|
| 18 | 22.7 |
|---|
| 19 | 22.8 |
|---|
| 20 | 22.8 |
|---|
| 21 | 22.8 |
|---|
| 22 | 22.8 |
|---|
| 23 | 22.8 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.8 |
|---|
| 1 | 22.8 |
|---|
| 2 | 22.8 |
|---|
| 3 | 22.8 |
|---|
| 4 | 22.8 |
|---|
| 5 | 22.8 |
|---|
| 6 | 22.8 |
|---|
| 7 | 22.8 |
|---|
| 8 | 22.8 |
|---|
| 9 | 22.8 |
|---|
| 10 | 22.8 |
|---|
| 11 | 22.9 |
|---|
| 12 | 22.9 |
|---|
| 13 | 22.9 |
|---|
| 14 | 22.9 |
|---|
| 15 | 22.9 |
|---|
| 16 | 22.9 |
|---|
| 17 | 22.9 |
|---|
| 18 | 22.9 |
|---|
| 19 | 22.9 |
|---|
| 20 | 22.9 |
|---|
| 21 | 22.9 |
|---|
| 22 | 22.9 |
|---|
| 23 | 22.9 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.9 |
|---|
| 1 | 22.9 |
|---|
| 2 | 22.9 |
|---|
| 3 | 23.0 |
|---|
| 4 | 23.0 |
|---|
| 5 | 23.0 |
|---|
| 6 | 23.0 |
|---|
| 7 | 23.0 |
|---|
| 8 | 23.0 |
|---|
| 9 | 23.0 |
|---|
| 10 | 23.0 |
|---|
| 11 | 23.0 |
|---|
| 12 | 23.0 |
|---|
| 13 | 23.0 |
|---|
| 14 | 23.0 |
|---|
| 15 | 23.0 |
|---|
| 16 | 23.0 |
|---|
| 17 | 23.0 |
|---|
| 18 | 23.0 |
|---|
| 19 | 23.0 |
|---|
| 20 | 23.0 |
|---|
| 21 | 23.1 |
|---|
| 22 | 23.1 |
|---|
| 23 | 23.1 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.1 |
|---|
| 1 | 23.1 |
|---|
| 2 | 23.1 |
|---|
| 3 | 23.1 |
|---|
| 4 | 23.1 |
|---|
| 5 | 23.1 |
|---|
| 6 | 23.1 |
|---|
| 7 | 23.1 |
|---|
| 8 | 23.1 |
|---|
| 9 | 23.1 |
|---|
| 10 | 23.1 |
|---|
| 11 | 23.1 |
|---|
| 12 | 23.1 |
|---|
| 13 | 23.1 |
|---|
| 14 | 23.1 |
|---|
| 15 | 23.2 |
|---|
| 16 | 23.2 |
|---|
| 17 | 23.2 |
|---|
| 18 | 23.2 |
|---|
| 19 | 23.2 |
|---|
| 20 | 23.2 |
|---|
| 21 | 23.2 |
|---|
| 22 | 23.2 |
|---|
| 23 | 23.2 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.2 |
|---|
| 1 | 23.2 |
|---|
| 2 | 23.2 |
|---|
| 3 | 23.2 |
|---|
| 4 | 23.2 |
|---|
| 5 | 23.2 |
|---|
| 6 | 23.2 |
|---|
| 7 | 23.2 |
|---|
| 8 | 23.2 |
|---|
| 9 | 23.2 |
|---|
| 10 | 23.2 |
|---|
| 11 | 23.3 |
|---|
| 12 | 23.3 |
|---|
| 13 | 23.3 |
|---|
| 14 | 23.3 |
|---|
| 15 | 23.3 |
|---|
| 16 | 23.3 |
|---|
| 17 | 23.3 |
|---|
| 18 | 23.3 |
|---|
| 19 | 23.3 |
|---|
| 20 | 23.3 |
|---|
| 21 | 23.3 |
|---|
| 22 | 23.3 |
|---|
| 23 | 23.3 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.3 |
|---|
| 1 | 23.3 |
|---|
| 2 | 23.3 |
|---|
| 3 | 23.3 |
|---|
| 4 | 23.3 |
|---|
| 5 | 23.3 |
|---|
| 6 | 23.3 |
|---|
| 7 | 23.3 |
|---|
| 8 | 23.3 |
|---|
| 9 | 23.4 |
|---|
| 10 | 23.4 |
|---|
| 11 | 23.4 |
|---|
| 12 | 23.4 |
|---|
| 13 | 23.4 |
|---|
| 14 | 23.4 |
|---|
| 15 | 23.4 |
|---|
| 16 | 23.4 |
|---|
| 17 | 23.4 |
|---|
| 18 | 23.4 |
|---|
| 19 | 23.4 |
|---|
| 20 | 23.4 |
|---|
| 21 | 23.4 |
|---|
| 22 | 23.4 |
|---|
| 23 | 23.4 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.4 |
|---|
| 1 | 23.4 |
|---|
| 2 | 23.4 |
|---|
| 3 | 23.4 |
|---|
| 4 | 23.4 |
|---|
| 5 | 23.4 |
|---|
| 6 | 23.4 |
|---|
| 7 | 23.4 |
|---|
| 8 | 23.4 |
|---|
| 9 | 23.4 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 36 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 23.5 |
|---|
| 1 | 23.5 |
|---|
| 2 | 23.5 |
|---|
| 3 | 23.5 |
|---|
| 4 | 23.5 |
|---|
| 5 | 23.5 |
|---|
| 6 | 23.5 |
|---|
| 7 | 23.5 |
|---|
| 8 | 23.5 |
|---|
| 9 | 23.5 |
|---|
| 10 | 23.5 |
|---|
| 11 | 23.5 |
|---|
| 12 | 23.5 |
|---|
| 13 | 23.5 |
|---|
| 14 | 23.5 |
|---|
| 15 | 23.5 |
|---|
| 16 | 23.5 |
|---|
| 17 | 23.5 |
|---|
| 18 | 23.5 |
|---|
| 19 | 23.5 |
|---|
| 20 | 23.5 |
|---|
| 21 | 23.5 |
|---|
| 22 | 23.5 |
|---|
| 23 | 23.5 |
|---|
AAP 2022 · Supplemental Table 4, PDF p26 →
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL
Additional risks: albumin <3.0 g/dL; isoimmune/G6PD/other hemolysis; sepsis; significant clinical instability in the preceding 24 h. For exchange escalation, KAS 17 also selects the additional-risk thresholds when TSB rises despite phototherapy.
Birth ≥35 weeks only. Read completed day and hour together. A dash means no value was published for that cell; no interpolation is supplied. Values retain the source’s one-decimal rounding.
Completed day 0
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 0| Hour on this day | TSB mg/dL |
|---|
| 0 | — |
|---|
| 1 | 13.1 |
|---|
| 2 | 13.3 |
|---|
| 3 | 13.4 |
|---|
| 4 | 13.6 |
|---|
| 5 | 13.7 |
|---|
| 6 | 13.8 |
|---|
| 7 | 14.0 |
|---|
| 8 | 14.1 |
|---|
| 9 | 14.3 |
|---|
| 10 | 14.4 |
|---|
| 11 | 14.5 |
|---|
| 12 | 14.6 |
|---|
| 13 | 14.8 |
|---|
| 14 | 14.9 |
|---|
| 15 | 15.0 |
|---|
| 16 | 15.1 |
|---|
| 17 | 15.3 |
|---|
| 18 | 15.4 |
|---|
| 19 | 15.5 |
|---|
| 20 | 15.6 |
|---|
| 21 | 15.8 |
|---|
| 22 | 15.9 |
|---|
| 23 | 16.0 |
|---|
Completed day 1
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 1| Hour on this day | TSB mg/dL |
|---|
| 0 | 16.1 |
|---|
| 1 | 16.2 |
|---|
| 2 | 16.3 |
|---|
| 3 | 16.4 |
|---|
| 4 | 16.5 |
|---|
| 5 | 16.6 |
|---|
| 6 | 16.8 |
|---|
| 7 | 16.9 |
|---|
| 8 | 17.0 |
|---|
| 9 | 17.1 |
|---|
| 10 | 17.2 |
|---|
| 11 | 17.3 |
|---|
| 12 | 17.4 |
|---|
| 13 | 17.5 |
|---|
| 14 | 17.6 |
|---|
| 15 | 17.7 |
|---|
| 16 | 17.7 |
|---|
| 17 | 17.8 |
|---|
| 18 | 17.9 |
|---|
| 19 | 18.0 |
|---|
| 20 | 18.1 |
|---|
| 21 | 18.2 |
|---|
| 22 | 18.3 |
|---|
| 23 | 18.4 |
|---|
Completed day 2
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 2| Hour on this day | TSB mg/dL |
|---|
| 0 | 18.5 |
|---|
| 1 | 18.5 |
|---|
| 2 | 18.6 |
|---|
| 3 | 18.7 |
|---|
| 4 | 18.8 |
|---|
| 5 | 18.9 |
|---|
| 6 | 18.9 |
|---|
| 7 | 19.0 |
|---|
| 8 | 19.1 |
|---|
| 9 | 19.2 |
|---|
| 10 | 19.2 |
|---|
| 11 | 19.3 |
|---|
| 12 | 19.4 |
|---|
| 13 | 19.4 |
|---|
| 14 | 19.5 |
|---|
| 15 | 19.6 |
|---|
| 16 | 19.6 |
|---|
| 17 | 19.7 |
|---|
| 18 | 19.8 |
|---|
| 19 | 19.8 |
|---|
| 20 | 19.9 |
|---|
| 21 | 19.9 |
|---|
| 22 | 20.0 |
|---|
| 23 | 20.1 |
|---|
Completed day 3
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 3| Hour on this day | TSB mg/dL |
|---|
| 0 | 20.1 |
|---|
| 1 | 20.2 |
|---|
| 2 | 20.2 |
|---|
| 3 | 20.3 |
|---|
| 4 | 20.3 |
|---|
| 5 | 20.4 |
|---|
| 6 | 20.4 |
|---|
| 7 | 20.5 |
|---|
| 8 | 20.5 |
|---|
| 9 | 20.6 |
|---|
| 10 | 20.6 |
|---|
| 11 | 20.6 |
|---|
| 12 | 20.7 |
|---|
| 13 | 20.7 |
|---|
| 14 | 20.8 |
|---|
| 15 | 20.8 |
|---|
| 16 | 20.8 |
|---|
| 17 | 20.9 |
|---|
| 18 | 20.9 |
|---|
| 19 | 20.9 |
|---|
| 20 | 21.0 |
|---|
| 21 | 21.0 |
|---|
| 22 | 21.0 |
|---|
| 23 | 21.1 |
|---|
Completed day 4
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 4| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.1 |
|---|
| 1 | 21.1 |
|---|
| 2 | 21.1 |
|---|
| 3 | 21.1 |
|---|
| 4 | 21.1 |
|---|
| 5 | 21.1 |
|---|
| 6 | 21.1 |
|---|
| 7 | 21.1 |
|---|
| 8 | 21.1 |
|---|
| 9 | 21.2 |
|---|
| 10 | 21.2 |
|---|
| 11 | 21.2 |
|---|
| 12 | 21.2 |
|---|
| 13 | 21.2 |
|---|
| 14 | 21.2 |
|---|
| 15 | 21.2 |
|---|
| 16 | 21.2 |
|---|
| 17 | 21.2 |
|---|
| 18 | 21.2 |
|---|
| 19 | 21.3 |
|---|
| 20 | 21.3 |
|---|
| 21 | 21.3 |
|---|
| 22 | 21.3 |
|---|
| 23 | 21.3 |
|---|
Completed day 5
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 5| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.3 |
|---|
| 1 | 21.3 |
|---|
| 2 | 21.3 |
|---|
| 3 | 21.3 |
|---|
| 4 | 21.3 |
|---|
| 5 | 21.4 |
|---|
| 6 | 21.4 |
|---|
| 7 | 21.4 |
|---|
| 8 | 21.4 |
|---|
| 9 | 21.4 |
|---|
| 10 | 21.4 |
|---|
| 11 | 21.4 |
|---|
| 12 | 21.4 |
|---|
| 13 | 21.4 |
|---|
| 14 | 21.4 |
|---|
| 15 | 21.4 |
|---|
| 16 | 21.5 |
|---|
| 17 | 21.5 |
|---|
| 18 | 21.5 |
|---|
| 19 | 21.5 |
|---|
| 20 | 21.5 |
|---|
| 21 | 21.5 |
|---|
| 22 | 21.5 |
|---|
| 23 | 21.5 |
|---|
Completed day 6
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 6| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.5 |
|---|
| 1 | 21.5 |
|---|
| 2 | 21.5 |
|---|
| 3 | 21.6 |
|---|
| 4 | 21.6 |
|---|
| 5 | 21.6 |
|---|
| 6 | 21.6 |
|---|
| 7 | 21.6 |
|---|
| 8 | 21.6 |
|---|
| 9 | 21.6 |
|---|
| 10 | 21.6 |
|---|
| 11 | 21.6 |
|---|
| 12 | 21.6 |
|---|
| 13 | 21.6 |
|---|
| 14 | 21.7 |
|---|
| 15 | 21.7 |
|---|
| 16 | 21.7 |
|---|
| 17 | 21.7 |
|---|
| 18 | 21.7 |
|---|
| 19 | 21.7 |
|---|
| 20 | 21.7 |
|---|
| 21 | 21.7 |
|---|
| 22 | 21.7 |
|---|
| 23 | 21.7 |
|---|
Completed day 7
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 7| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.7 |
|---|
| 1 | 21.8 |
|---|
| 2 | 21.8 |
|---|
| 3 | 21.8 |
|---|
| 4 | 21.8 |
|---|
| 5 | 21.8 |
|---|
| 6 | 21.8 |
|---|
| 7 | 21.8 |
|---|
| 8 | 21.8 |
|---|
| 9 | 21.8 |
|---|
| 10 | 21.8 |
|---|
| 11 | 21.8 |
|---|
| 12 | 21.8 |
|---|
| 13 | 21.9 |
|---|
| 14 | 21.9 |
|---|
| 15 | 21.9 |
|---|
| 16 | 21.9 |
|---|
| 17 | 21.9 |
|---|
| 18 | 21.9 |
|---|
| 19 | 21.9 |
|---|
| 20 | 21.9 |
|---|
| 21 | 21.9 |
|---|
| 22 | 21.9 |
|---|
| 23 | 21.9 |
|---|
Completed day 8
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 8| Hour on this day | TSB mg/dL |
|---|
| 0 | 21.9 |
|---|
| 1 | 22.0 |
|---|
| 2 | 22.0 |
|---|
| 3 | 22.0 |
|---|
| 4 | 22.0 |
|---|
| 5 | 22.0 |
|---|
| 6 | 22.0 |
|---|
| 7 | 22.0 |
|---|
| 8 | 22.0 |
|---|
| 9 | 22.0 |
|---|
| 10 | 22.0 |
|---|
| 11 | 22.0 |
|---|
| 12 | 22.0 |
|---|
| 13 | 22.0 |
|---|
| 14 | 22.1 |
|---|
| 15 | 22.1 |
|---|
| 16 | 22.1 |
|---|
| 17 | 22.1 |
|---|
| 18 | 22.1 |
|---|
| 19 | 22.1 |
|---|
| 20 | 22.1 |
|---|
| 21 | 22.1 |
|---|
| 22 | 22.1 |
|---|
| 23 | 22.1 |
|---|
Completed day 9
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 9| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.1 |
|---|
| 1 | 22.1 |
|---|
| 2 | 22.2 |
|---|
| 3 | 22.2 |
|---|
| 4 | 22.2 |
|---|
| 5 | 22.2 |
|---|
| 6 | 22.2 |
|---|
| 7 | 22.2 |
|---|
| 8 | 22.2 |
|---|
| 9 | 22.2 |
|---|
| 10 | 22.2 |
|---|
| 11 | 22.2 |
|---|
| 12 | 22.2 |
|---|
| 13 | 22.2 |
|---|
| 14 | 22.2 |
|---|
| 15 | 22.2 |
|---|
| 16 | 22.3 |
|---|
| 17 | 22.3 |
|---|
| 18 | 22.3 |
|---|
| 19 | 22.3 |
|---|
| 20 | 22.3 |
|---|
| 21 | 22.3 |
|---|
| 22 | 22.3 |
|---|
| 23 | 22.3 |
|---|
Completed day 10
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 10| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.3 |
|---|
| 1 | 22.3 |
|---|
| 2 | 22.3 |
|---|
| 3 | 22.3 |
|---|
| 4 | 22.3 |
|---|
| 5 | 22.3 |
|---|
| 6 | 22.4 |
|---|
| 7 | 22.4 |
|---|
| 8 | 22.4 |
|---|
| 9 | 22.4 |
|---|
| 10 | 22.4 |
|---|
| 11 | 22.4 |
|---|
| 12 | 22.4 |
|---|
| 13 | 22.4 |
|---|
| 14 | 22.4 |
|---|
| 15 | 22.4 |
|---|
| 16 | 22.4 |
|---|
| 17 | 22.4 |
|---|
| 18 | 22.4 |
|---|
| 19 | 22.4 |
|---|
| 20 | 22.5 |
|---|
| 21 | 22.5 |
|---|
| 22 | 22.5 |
|---|
| 23 | 22.5 |
|---|
Completed day 11
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 11| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.5 |
|---|
| 1 | 22.5 |
|---|
| 2 | 22.5 |
|---|
| 3 | 22.5 |
|---|
| 4 | 22.5 |
|---|
| 5 | 22.5 |
|---|
| 6 | 22.5 |
|---|
| 7 | 22.5 |
|---|
| 8 | 22.5 |
|---|
| 9 | 22.5 |
|---|
| 10 | 22.5 |
|---|
| 11 | 22.6 |
|---|
| 12 | 22.6 |
|---|
| 13 | 22.6 |
|---|
| 14 | 22.6 |
|---|
| 15 | 22.6 |
|---|
| 16 | 22.6 |
|---|
| 17 | 22.6 |
|---|
| 18 | 22.6 |
|---|
| 19 | 22.6 |
|---|
| 20 | 22.6 |
|---|
| 21 | 22.6 |
|---|
| 22 | 22.6 |
|---|
| 23 | 22.6 |
|---|
Completed day 12
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 12| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.6 |
|---|
| 1 | 22.6 |
|---|
| 2 | 22.6 |
|---|
| 3 | 22.7 |
|---|
| 4 | 22.7 |
|---|
| 5 | 22.7 |
|---|
| 6 | 22.7 |
|---|
| 7 | 22.7 |
|---|
| 8 | 22.7 |
|---|
| 9 | 22.7 |
|---|
| 10 | 22.7 |
|---|
| 11 | 22.7 |
|---|
| 12 | 22.7 |
|---|
| 13 | 22.7 |
|---|
| 14 | 22.7 |
|---|
| 15 | 22.7 |
|---|
| 16 | 22.7 |
|---|
| 17 | 22.7 |
|---|
| 18 | 22.7 |
|---|
| 19 | 22.7 |
|---|
| 20 | 22.8 |
|---|
| 21 | 22.8 |
|---|
| 22 | 22.8 |
|---|
| 23 | 22.8 |
|---|
Completed day 13
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 13| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.8 |
|---|
| 1 | 22.8 |
|---|
| 2 | 22.8 |
|---|
| 3 | 22.8 |
|---|
| 4 | 22.8 |
|---|
| 5 | 22.8 |
|---|
| 6 | 22.8 |
|---|
| 7 | 22.8 |
|---|
| 8 | 22.8 |
|---|
| 9 | 22.8 |
|---|
| 10 | 22.8 |
|---|
| 11 | 22.8 |
|---|
| 12 | 22.8 |
|---|
| 13 | 22.9 |
|---|
| 14 | 22.9 |
|---|
| 15 | 22.9 |
|---|
| 16 | 22.9 |
|---|
| 17 | 22.9 |
|---|
| 18 | 22.9 |
|---|
| 19 | 22.9 |
|---|
| 20 | 22.9 |
|---|
| 21 | 22.9 |
|---|
| 22 | 22.9 |
|---|
| 23 | 22.9 |
|---|
Completed day 14
AAP 2022 · Exchange transfusion · GA 35 weeks · Additional neurotoxicity risk factor(s) · TSB mg/dL · Completed day 14| Hour on this day | TSB mg/dL |
|---|
| 0 | 22.9 |
|---|
| 1 | 22.9 |
|---|
| 2 | 22.9 |
|---|
| 3 | 22.9 |
|---|
| 4 | 22.9 |
|---|
| 5 | 22.9 |
|---|
| 6 | 22.9 |
|---|
| 7 | 22.9 |
|---|
| 8 | 22.9 |
|---|
| 9 | 22.9 |
|---|
| 10 | 22.9 |
|---|
| 11 | 22.9 |
|---|
| 12 | 22.9 |
|---|
| 13 | 22.9 |
|---|
| 14 | 22.9 |
|---|
| 15 | 22.9 |
|---|
| 16 | 22.9 |
|---|
| 17 | 22.9 |
|---|
| 18 | 22.9 |
|---|
| 19 | 22.9 |
|---|
| 20 | 22.9 |
|---|
| 21 | 22.9 |
|---|
| 22 | 22.9 |
|---|
| 23 | 22.9 |
|---|
AAP 2022 · Supplemental Table 4, PDF p26 →